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Abstract
CD4+ T cells make a crucial contribution to the development of inflammatory arthritis both in humans and
in mouse models. However, how the affinity with which T cells recognize target antigens might shape
disease development and influence treatment modalities is poorly understood. We have examined these
phenomena in mouse models of autoimmune arthritis: TS1xHACII and TS1(SW)xHACII mice express
influenza hemagglutinin (HA) as a neo-self peptide and co-express transgenic TCRs that have either high
affinity (TS1xHACII) or low affinity (TS1(SW)xHACII) for the HA-derived MHCII determinant, S1. Despite
extensive deletion of T cells bearing autoreactive TCRs, arthritis spontaneously develops in both strains.
In TS1xHACII mice, males and females develop arthritis equally. CD4+ T cells in this setting display high
reactivity to the S1 self-antigen and disease is accompanied by high levels of pro-inflammatory cytokines.
Arthritis was found to develop by a B cell-independent mechanism in TS1xHACII mice, although it can be
suppressed by anti-IL-17 and anti-TNF treatments, the latter which prevented the accumulation of effector
CD4+IL-17+ cells in the joints of treated mice. By contrast, arthritis develops with a significant female bias
in the context of a more weakly autoreactive CD4+ T cell response in TS1(SW)xHACII mice and disease
was accompanied by lower levels of inflammatory cytokines. IL-17 is also required for disease
development in this setting as well; B cells, in this case however, were found to play a prominent role in
disease pathogenesis. Rather than acting as a source of arthritogenic autoantibodies, B cells appear to
serve as APCs to promote the formation of autoreactive CD4+ effector T cells (including Th17 cells).
Unlike in TS1xHACII mice, anti-TNF treatment appears to modulate disease severity but was insufficient
to ameliorate the onset of disease in TS1(SW)xHACII mice. These studies demonstrate that variations in
the CD4+ T cell response to a single target autoantigen can play a prominent role in guiding the pathways
to inflammatory arthritis development. These studies may also explain why treatment modalities
targeting particular pathways (cytokines vs B cells) can exhibit different efficacies in arthritis patients.
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ABSTRACT

THE INFLUENCE OF CD4+ T CELL AFFINITY FOR SELF-ANTIGEN ON
THE DEVELOPMENT OF INFLAMMATORY ARTHRITIS
Olivia A. Perng
Andrew J. Caton, Ph.D.

CD4+ T cells make a crucial contribution to the development of inflammatory
arthritis both in humans and in mouse models. However, how the affinity with which T
cells recognize target antigens might shape disease development and influence
treatment modalities is poorly understood. We have examined these phenomena in
mouse models of autoimmune arthritis: TS1xHACII and TS1(SW)xHACII mice express
influenza hemagglutinin (HA) as a neo-self peptide and co-express transgenic TCRs that
have either high affinity (TS1xHACII) or low affinity (TS1(SW)xHACII) for the HA-derived
MHCII determinant, S1. Despite extensive deletion of T cells bearing autoreactive
TCRs, arthritis spontaneously develops in both strains. In TS1xHACII mice, males and
females develop arthritis equally. CD4+ T cells in this setting display high reactivity to
the S1 self-antigen and disease is accompanied by high levels of pro-inflammatory
cytokines. Arthritis was found to develop by a B cell-independent mechanism in
TS1xHACII mice, although it can be suppressed by anti-IL-17 and anti-TNF treatments,
the latter which prevented the accumulation of effector CD4+IL-17+ cells in the joints of
treated mice. By contrast, arthritis develops with a significant female bias in the context
of a more weakly autoreactive CD4+ T cell response in TS1(SW)xHACII mice and
disease was accompanied by lower levels of inflammatory cytokines. IL-17 is also
iv

required for disease development in this setting as well; B cells, in this case however,
were found to play a prominent role in disease pathogenesis. Rather than acting as a
source of arthritogenic autoantibodies, B cells appear to serve as APCs to promote the
formation of autoreactive CD4+ effector T cells (including Th17 cells). Unlike in
TS1xHACII mice, anti-TNF treatment appears to modulate disease severity but was
insufficient to ameliorate the onset of disease in TS1(SW)xHACII mice. These studies
demonstrate that variations in the CD4+ T cell response to a single target autoantigen
can play a prominent role in guiding the pathways to inflammatory arthritis development.
These studies may also explain why treatment modalities targeting particular pathways
(cytokines vs B cells) can exhibit different efficacies in arthritis patients.
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Chapter 1: Introduction and Overview

1.1 Introduction

The stochastic generation of antigen receptors expressed by cells of the adaptive
immune system allows for their ability to mount a targeted response towards diverse
pathogens. In generating this vast antigen receptor repertoire, specificities that are selfreactive undoubtedly appear. Dysregulation of the immune system results in the
development of human autoimmune diseases. In this chapter, we give a brief overview
of the adaptive immune system and the development of autoimmune diseases such as
inflammatory arthritis.

1.2 The adaptive immune system

The adaptive immune system evolved to combat an enormous array of
pathogens such as viruses, bacteria and parasites. It is the specificity and functional
diversity of this arm of the immune system that allows for a tailored anti-pathogen
response and is the hallmark of adaptive immunity. This section briefly describes the
development and differentiation of cells that comprise the adaptive immune system.

1

1.2.1 Development of adaptive immune cells

Development of cells of the adaptive immune system begins with a common
hematopoetic precursor which then either travels to the thymus and develops into T cells
or remains in the bone marrow and develops into B cells (Wu et al. 1991, Spooner et al.
2009). Maturation and differentiation of these precursor cells into T or B cells occur
through several steps which involve signaling through their antigen receptors and
acquisition of a unique transcriptional profile (Starr et al. 2003, Pelanda and Torres
2012). The antigen receptors on T cells (T cell receptor, TCR) and B cells (B cell
receptor, BCR; immunoglobulins, Igs) are produced by gene rearrangement
mechanisms. Of note, the BCR of B cells can be secreted from the cell as soluble Igs
(also known as antibodies) of the same specificity. Briefly, germ-line sequences of
genes that comprise each subunit of the TCR (TCR - and β-chains; and less common
TCR - and -chains) and BCR (Ig-heavy and Ig-light chains) undergo gene
rearrangements in a complex with the RAG 1/2 recombinase enzyme. Although each
step of the gene rearrangement process is strictly and sequentially regulated, the
combinations resulting from the rearrangement process are random (stochastic).
Furthermore, this receptor rearrangement process occurs in each cell. As each cell
bears a unique antigen receptor, this generates a pool of lymphocytes with a highly
diverse receptor repertoire. Mathematically, for each lymphocyte subset approximately
1015 different receptor combinations are possible (Davis and Bjorkman 1988).

However, not all combinations are productive; cells that do not make productive
rearrangements are not signaled to survive. Moreover, if a cell does generate a
2

functional receptor, they are subjected to repertoire selection processes. For T cells,
they undergo positive and negative selection in the thymus. Thymocytes which cannot
receive a signal through their TCR undergo apoptosis (positive selection) and those that
are too strongly reactive to self-antigen are deleted (negative selection) (Ashton-Rickardt
et al. 1994, Sebzda et al. 1994). Immature B cells that react with self-antigen with high
avidity are shuttled down an apoptotic pathway (clonal deletion) whereas those with low
avidity reactions are left to survive (Pelanda and Torres 2012). Additionally, B cells can
undergo editing of their BCRs following a previous high avidity reaction with self-antigen
(receptor editing). The end product is that each cell expresses a unique antigen
receptor. Since the process of gene rearrangements used to generate TCRs and BCRs
is stochastic, this results in an enormous diversity of receptors with distinct antigenic
specificities.

1.2.2 Activation and effector functions of the adaptive immune system

A. T cells

T cells and B cells must receive a signal through their antigen receptors to
become activated and capable of mounting an effector response. We will first address
activation and differentiation of T cells. With respect to T cells, antigen must be
presented in the form of a peptide bound to major histocompatibility complexes (MHC) –
either MHC class I for CD8+ T cells or MHC class II (MHCII) for CD4+ T cells – to be able
to be recognized by a TCR (Zijlstra et al. 1990, Cosgrove et al. 1991). MHC class I is
expressed on all nucleated cells and presents peptides which are cytosolically derived.
3

On the other hand, MHCII expression is typically restricted to a subset of cells termed
professional antigen presenting cells (APCs) and presents peptides derived from
internally synthesized proteins and external proteins (both self and foreign) that were
endocytosed. Cells types that are classified as APCs include dendritic cells (DC),
macrophages as well as B cells.

In naïve T cells, intracellular signals converge downstream of the TCR upon
interaction with antigens presented by the appropriate MHC, which leads to upregulated
transcription and translation of multiple genes and entry of the cell into cell cycle (SmithGarvin et al. 2009, Zhu and Paul 2010, Wang et al. 2011). Aside from the TCR,
secondary signals, through either co-receptors and/or cytokine receptors, can instruct
newly activated cells to differentiate into distinct, effector phenotypes. For CD4+ T cells,
these signals would promote polarization into various T helper (Th) subsets, each
capable of secreting characteristic patterns of cytokines that are tailored for specific
subsets of pathogens (Mosmann et al. 1986, Cherwinski et al. 1987, Park et al. 2005).
Polarization of CD4+ T cells toward the Th1 lineage has been shown to require IL-12;
following TCR and IL-12 signaling, the cell then acquires and expresses the transcription
factor T-bet which promotes the production of IFN-, the characteristic Th1 cytokine.
Th1 responses are generated to effectively combat intracellular bacteria. Th2 cells
develop in the presence of IL-4, express the transcription factor GATA-3, and secrete IL4, IL-5, and IL-13; Th2 responses are generated to combat extracellular pathogens such
as parasitic worms. One of the more recent T helper lineages, Th17 cells develop in the
presence of TGF- and IL-6, express the transcription factor RORt, and secrete IL-17A

4

(herein referred to as IL-17), IL-17F, IL-21 and IL-22; Th17 responses are necessary for
defense against extracellular bacteria.

CD8+ T cells, upon activation, acquire the ability to produce various inflammatory
cytokines such as IFN- and TNF- (herein referred to as TNF) as well as perforin and
granzyme (both cytolytic proteins, which when released, perforate and induce apoptotic
damage in target cells (Sarin et al. 1997). CD8+ T cell responses are necessary to
combat virus infections. Similar to CD4+ T cells, CD8+ T cells acquire differentiation
programs which direct them to either short-lived effector cell or long-lived memory cell
fates (Wherry and Ahmed 2004). When CD8+ T cells commit to becoming either shortlived effector or long-lived memory cells has not been agreed upon (Wiesel et al. 2009).

Notably, in addition to the stimulation through their TCR, T cells must receive a
secondary signal through co-stimulatory receptors that is delivered by the same cell on
which the antigen is presented. If this second co-stimulatory signal is not received, T
cells fail to activate and enter into a state called functional anergy in which the cell is
rendered inactive and cannot be re-stimulated through the TCR but the addition of IL-2
can reverse this block (Jenkins and Schwartz 1987, Quill and Schwartz 1987). Of note,
intravenous injections of high doses of antigen can also induce functional anergy (Oki
and Sercarz 1985). It can be reasoned that this mechanism is in place so that T cells
can be activated by foreign antigens derived from invading pathogens, which causes
upregulation of co-stimulatory ligands that are typically absent or reduced at steady
state, rather than self-antigens, and constitute a mechanism of self- tolerance (Liu and
Janeway 1992).
5

B. B cells

We next address the activation of B cells. BCRs, unlike TCRs, recognize threedimensional structures rather than peptides (LeBien and Tedder 2008, Harwood and
Batista 2010). More specifically, the structures/epitopes BCRs recognize include areas
of naturally folded proteins as well as polysaccharides. Antigen recognition followed by
cross-linking of BCRs on the surface of a B cell, initiates downstream signaling events
resulting in their activation (LeBien and Tedder 2008, Harwood and Batista 2010). One
of the main functions of B cells is the production of antibodies, which are secreted forms
of the membrane bound BCR. Antibodies are useful for immunity against pathogens
because they can bind and neutralize certain epitopes, bind to antigen and elicit a
complement cascade, or bind to antigen to mark them for phagocytosis (LeBien and
Tedder 2008, Schroeder and Cavacini 2010). In order to generate and secrete
antibodies, activated B cells follow a step-wise program which directs not only the events
to modify the BCR/Ig into one that is of high affinity for an antigen (somatic
hypermutation), but this program also directs the Ig to “class switch”, e.g. from IgM to
IgG, and directs the differentiation of B cells into a highly specialized subset called
plasma cells, whose main purpose is to produce large quantities of antibodies (LeBien
and Tedder 2008).

In response to many antigens, B cells require CD4+ T cell “help” in order to
differentiate into plasma cells (Parker 1993). This appears to be a regulatory
mechanism that needs to be fulfilled in order to license antibody production. Effector
CD4+ T cells provide help to B cells through engagement of co-stimulatory receptors and
through provision of cytokines. A key factor in this process is that B cells, acting as
6

APCs, must present the appropriate antigen (which the B cell previously acquired
through its BCR and internalized) bound to MHCII on its surface to the TCR on the
effector CD4+ T helper cell. This event, termed linked recognition, allows for the directed
development of an immune response toward a certain pathogen. Of note, the epitope
which the BCR recognizes does not need to be the same epitope that the TCR
recognizes. However, it is crucial that the TCR epitope is part of the antigen complex in
which the BCR recognizes. A further extrapolation of this concept is that a known
antibody specificity can link the involvement of CD4+ T cells that recognize the same
antigen. Of note, B cells can also be activated to produce antibodies in a T cellindependent manner (Mond et al. 1995).

Altogether, CD4+ T cells, CD8+ T cells and B cells each have unique functions
but many times they elaborate their effector functions in concert to eliminate hazardous
and infectious pathogens.

C. Foxp3+ regulatory T cells

Foxp3+ regulatory T cells (Tregs) constitute a unique subset of CD4+ T cells.
Unlike conventional CD4+ T cells (non-Foxp3+), this subset mounts an
immunosuppressive rather than an immunostimulatory response upon activation. The
discovery of this subset and its critical impact on regulating autoimmune responses was
following seminal work demonstrating that the autoimmune pathology induced by
conventional CD4+ T cells (CD4+CD25-) can be prevented by the co-transfer of a
CD4+CD25+ population (Sakaguchi et al. 1995). Further assessment has indicated that
5-10% of the peripheral CD4+ T cell repertoire co-express CD25 (the high affinity IL-2Ra
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subunit) and that their suppressive function can be conferred by the expression of the
transcription factor Foxp3 (Sakaguchi et al. 1995, Itoh et al. 1999, Fontenot et al. 2003,
Hori et al. 2003). Tregs can be generated and selected for in the thymus by high affinity
cognate ligands, which does not fit the paradigm for how T cells are typically selected
(Jordan et al. 2001). Alternatively, Tregs can be induced from conventional CD4+CD25Foxp3- cells in the periphery by various means (Chen et al. 2003, Coombes et al. 2007);
although peripherally induced Tregs may resemble thymically derived Tregs these two
populations differ in several respects (transcription profile, TCR repertoire) (Curotto de
Lafaille and Lafaille 2009).

Tregs are reported capable of having numerous modes of action some of which
include suppression of APC function, production of inhibitory cytokines such as IL-10
and TGF-, and competition for IL-2 (Sakaguchi et al. 2008, Shevach 2009). This
subset plays an important role in modulating and preventing over-exuberant immune
responses mounted against pathogen. However, much work has been directed toward
elucidating Treg functions (or lack of) in autoimmune settings. Moreover, Tregs are also
considered an essential mechanism of peripheral tolerance since people and mice
lacking Tregs develop severe autoimmune syndromes (Sakaguchi et al. 2008).

1.3 Inflammatory arthritis in humans

The adaptive immune system, evolved to efficiently control harmful pathogens,
can also elicit self-destruction if not properly regulated. Due to how antigen receptors
are generated, to various degrees, T and B cells present in the body are self-reactive
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and can be capable of inducing autoimmunity. However, as briefly described in the
previous section, multiple mechanisms of tolerance induction exist (both central and
peripheral) that eliminate or functionally suppress highly self-reactive cells to prevent this
from occurring (Palmer 2003, Hogquist et al. 2005, Mueller 2010). Indeed, these
mechanisms of tolerance induction have proven capable of controlling autoimmunity in
the majority of individuals since only 3 to 5 percent of the population develops
autoimmune diseases (Marrack et al. 2001). Actually, it is through the study of
autoimmune diseases that has allowed us gain insight into mechanisms of immune
regulation as it would be hard to do so in healthy individuals. Many autoimmune
diseases are restricted to a certain organs or tissues (organ-specific), however there are
some that are classified as “systemic” (Marrack et al. 2001). One of the most prominent
manifestations of systemic autoimmune diseases is inflammatory arthritis. The following
section addresses the development of inflammatory arthritis in humans.

1.3.1 Characterization of inflammatory arthritis

Inflammatory arthritis is a chronic, debilitating syndrome that arises in several
autoimmune disorders, including rheumatoid arthritis (RA), in which it is the most
prominent manifestation (McInnes and Schett 2011). Other settings in which
inflammatory arthritis appears are: psoriatic arthritis, juvenile idiopathic arthritis,
ankylosing spondylitis (AS), systemic lupus erythematosus (SLE), and inflammatory
bowel disease (IBD) (Gelber et al. 2010). Inflammatory arthritis by definition is the
inflammation of the joints, which is more specifically characterized by hyperplasia of the
synovial membranes in the joints and extensive infiltration of a variety of immune cells
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including neutrophils, macrophages, T cells and B cells (McInnes and Schett 2011).
Later, more advanced stages of the syndrome, are characterized by the formation of
pannus and the invasion of the synovial fibroblasts and macrophages into the cartilage
which leads to the degradation of the cartilage and bone. Settings in which inflammatory
arthritis presents are also associated with several systemic features including elevated
levels of pro-inflammatory cytokines, such as IL-1, TNF and IL-6, and the presence of
autoantibodies, such as rheumatoid factor (RF), antibodies against citrullinated peptides
(anti-CCP) and antibodies against double stranded DNA (anti-dsDNA), which can be
detected in the serum (McInnes and Schett 2011). The contribution of these factors to
disease development will be discussed in section 1.3.3.

1.3.2 Etiology and susceptibility

The etiology of inflammatory arthritis is largely unknown. However, strong
associations can be made with certain genetic and environmental factors.

A role for a genetic disposition to inflammatory arthritis was initially proposed
following the observation that disease tends to occur more often in genetically related
family members compared to the general populace (Lipsky 1998). Furthermore, disease
association studies revealed that disease concordance in monozygotic twins was ~15%
compared to ~2-5% in dizygotic twins, which was not more so than the rates between
family members (Firestein 2009). Moreover, it was discovered that susceptibility to
inflammatory arthritis is strongly linked to particular MHCII alleles since patients with
rheumatic diseases bear certain MHCII alleles more often than healthy individuals.
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These alleles are: HLA-DR4 (DRB1*401, *404, *101) in RA, HLA-DR2 (DRB1*1501)
and HLA-DR3 (DRB1*0301) in SLE, and HLA-B27 in AS (Clarke and Vyse 2009).

Because there is incomplete disease concordance between monozygotic twins, it
has been suggested that non-heritable factors (such as environmental agents and/or
stochastic events) can also contribute to the etiology of inflammatory arthritis. Some of
these candidate environmental agents include pathogens (Epstein-Barr virus,
mycoplasma, retroviruses) and tobacco (Firestein 2009). Several mechanisms have
been proposed to explain how these factors can initiate an autoimmune disease.
Probably the most accepted explanation is that these factors trigger an overt, nonspecific innate immune response which then allows for the bystander activation of
autoreactive T and B cells (Fujinami et al. 2006). Another explanation is that these
factors contain antigenic sites that have high homology to self-antigens, thereby
activating self-reactive T cells through “molecular mimicry” (Oldstone 1998), possibly
because the antigens in this case are presented by certain MHCs, such as those linked
to disease susceptibility. An alternative reason for the incomplete concordance
observed between twins is that stochastic events, such as those that generate TCR
repertoires, can influence susceptibility. This explanation would not preclude the
possibility of molecular mimicry. Variations in TCR repertoire formation is by far the
hardest correlation to prove in humans due to the vast repertoire each individual
possesses. However, this issue can begin to be addressed in mice (see Sections 1.4
and 1.5).
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Although the etiology of inflammatory arthritis remains unclear, several lines of
evidence, especially the genetic associations with disease susceptibility, implicate a
central role for CD4+ T cells in disease development.

1.3.3 Disease pathogenesis

The involvement of multiple cellular subsets and soluble factors has been
demonstrated in the development of inflammatory arthritis. The complex networks that
form, contrived of these cells and factors, has made elucidating the pathways of
pathogenesis in arthritis difficult yet intriguing (McInnes and Schett 2011). We examine
some of the cells and factors implicated in disease pathogenesis here and explore how
they can direct joint destruction.

A. Inflammatory cytokines

A key feature of autoimmune arthritis is the highly inflammatory nature of the
disease, as compared to osteoarthritis (also a joint disease but believed to be caused by
mechanical stress rather than an autoimmune reaction) (Farahat et al. 1993, Hampel et
al. 2013). Not only are high levels of multiple inflammatory cytokines found directly in
the inflamed joint, but elevated levels of cytokines can also be found in the serum, hence
the “systemic” nature of the disease (Steiner et al. 1999, Ziolkowska et al. 2000,
Feldmann 2002, McInnes and Schett 2011, Metawi et al. 2011). The cytokines that have
gained the most attention include: TNF, IL-1, IL-6, and more recently, IL-17. IL-1 can
induce proliferation of synovial cells and production of matrix metalloproteinases (MMPs)
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that can directly lead to cartilage destruction (Pettipher et al. 1986, van de Loo and van
den Berg 1990). Constitutively high levels of IL-6 can be found during active arthritis
and correlates with disease severity (Md Yusof and Emery 2013). Although a pleiotropic
cytokine, with regard to joint destruction, IL-6 has been demonstrated to promote MMPs
and osteoclast formation which leads to bone resorption. A breakthrough in elucidating
the pathways of pathogenesis in inflammatory arthritis was due to findings
demonstrating that TNF is at the top of a pro-inflammatory cascade that can perpetuate
as well as synergize with IL-1 and IL-6 to drive joint destruction (Feldmann 2002). In
addition to TNF, IL-1 and IL-6, highly elevated levels of IL-17 have also been discovered
in the synovial fluid of arthritis patients (Ziolkowska et al. 2000, Metawi et al. 2011). It
has been proposed that IL-17 can synergize with TNF and IL-1 to perpetuate the
production of inflammatory cytokines, induce RANKL in osteoblasts (which leads to bone
erosion), as well as induce the generation and recruitment of joint-destructive neutrophils
(Lubberts et al. 2005, Lubberts 2008). Interestingly, IL-6 and IL-1 appear to be important
for the in vitro differentiation of Th17 cells (a distinct lineage of T helper cells that
primarily produce IL-17, IL-17F, IL-21 and IL-22) (Park et al. 2005, Bettelli et al. 2006,
Mangan et al. 2006).

Thus, these findings demonstrate not only how inflammatory cytokines can lead
to a joint-targeted disease but that they can work in interconnecting networks to promote
arthritis development.
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B. CD4+ T cells

Due to the strong association between certain MHC Class II alleles and the
development of RA, CD4+ T cells have been implicated to play a central role in the
pathogenesis of disease (Clarke and Vyse 2009, McInnes and Schett 2011). Indeed,
CD4+ T cells can be found in inflamed joints of RA patients, bearing an activated
phenotype as illustrated by the expression of markers of antigen experience (CD69,
CD44, CD62Llo) and the expression of chemokine receptors (CCR6, CCR5, CXCR3)
used to direct the migration of these cells toward their ligands expressed in the joints
(Katschke et al. 2001, Firestein 2009). Importantly, joint-infiltrating CD4+ T cells were
found capable of producing inflammatory cytokines such as TNF, IFN- and IL-17
(Steiner et al. 1999, Firestein 2009).

C. B cells and autoantibodies

A classic test used for the diagnosis of RA assesses the presence and level of
rheumatoid factor (RF) (Firestein 2003, McInnes and Schett 2011). More recently, tests
determining the presence and level of anti-cyclic citrullinated peptide (anti-CCP) have
been used in conjunction with those for RF (Zendman et al. 2006). RF and anti-CCP are
autoantibodies that recognize the Fc portion of self-IgG and self-proteins that have
gained a citrullinated amino acid reside, respectively. The presence of these
autoantibodies (patients that test positive are categorized as “seropositive”) not only
indicates a break in self-tolerance but also implicates the involvement of autoantibodies
in disease pathogenesis. A proposed mode of action in which autoantibodies contribute
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to disease is that they form immune complexes that deposit in the joints, triggering a
joint-destructive complement cascade (Firestein 2003). Moreover, “seropositive”
patients tend to develop a more aggressive form of arthritis (Firestein 2009). It is
notable that ~20% of patients that present with symptoms of RA do not contain
detectable/elevated levels of RF or anti-CCP in their serum (categorized as
“seronegative”), suggesting that autoantibodies are not required for arthritis
development. Furthermore, the presence of elevated RF titers does not absolutely
dictate disease onset, further opposing an essential pathogenic role for autoantibodies in
arthritis development.

The extent to which B cells and autoantibodies contribute to disease
pathogenesis remains unclear in humans. Nonetheless, in order to generate high affinity
autoantibodies, it was likely that CD4+ T cell help was solicited. This would usually
happen in the spleen or LNs, but histological analysis of joint biopsies from some
arthritis patients show follicle-like structures where aggregates of B cells, T cells and
follicular DC can be found and appear to function as ectopic germinal centers (Schroder
et al. 1996). The appearance of these structures, however, can vary between patients
ranging from diffuse infiltrates to distinct follicles (Wagner et al. 1998, Weyand and
Goronzy 2003).

D. Regulatory T cells

Interestingly, several studies have indicated that autoimmune arthritis can
develop despite the presence of CD4+CD25+ Tregs (de Kleer et al. 2004, Ruprecht et al.
2005, Cao et al. 2006). Moreover, it appears that Tregs were also found to be enriched
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within the joints of arthritis patients. A potential explanation would be that Tregs in
arthritis patients, although representatively increased, are dysfunctional. In support of
this, Tregs isolated from RA patients exhibited reduced suppressor function (Ehrenstein
et al. 2004, Valencia et al. 2006, Nie et al. 2013). Notably, Ehrenstein et al. showed that
proliferation but not cytokine production could be suppressed with Tregs from arthritis
patients. And Nie et al. showed that Tregs isolated from the joints, but not the blood, of
RA patients displayed reduced suppressor function. However, a study performed with
Tregs isolated from juvenile idiopathic arthritis (JIA) patients provided a contrasting
result (de Kleer et al. 2004). In an in vitro suppression assay, Tregs isolated from the
synovial fluid of JIA patients suppressed more effectively than those isolated from the
blood. Thus, conflicting results exist on whether the dysfunction of Tregs contributes to
the development of inflammatory arthritis.

1.3.4 Treatments for RA

Generally, treatment for RA begins with a course of nonsteroidal antiinflammatory drugs (NSAIDs) and/or disease-modifying antirheumatic drugs (DMARDs)
that non-specifically suppress inflammation (Isaacs 2010). However, many patients
either fail to develop a response or do not maintain an adequate response to these
drugs. There are currently several treatment courses available when this happens, each
developed to target specific pathways believed to promote the pathogenesis of arthritis.
We discuss some of these treatments and their efficacy here.
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A. Anti-TNF

Since their conception and development in the 1990’s, anti-TNF regents remain
the next course of treatment for RA patients following NSAID/DMARD failure. This is
because anti-TNF treatments have a history of high and rapid response rates in RA
patients (Lipsky et al. 2000, Feldmann 2002). Successful responses to anti-TNF
treatment can be seen in upwards of 80% of patients and show efficacy as early as 2
weeks in some patients. Some mechanisms by which anti-TNF treatment is thought to
work include: inhibiting the production of pro-inflammatory cytokines in the joints and
reducing the expression of chemokines in the joints which prevents cell trafficking
(Taylor et al. 2000, Feldmann 2002). Interestingly, several studies have demonstrated
that anti-TNF treatment can also improve Treg suppressor function (Ehrenstein et al.
2004, Valencia et al. 2006, Nie et al. 2013). Valencia X et al. and Nie H et al. further
demonstrated that the addition of TNF to in vitro cultures can significantly impair the
suppressive ability of Tregs. Thus, anti-TNF treatment appears capable of suppressing
arthritis development through multiple modes of action. However, it is also possible that
these findings are an indirect consequence of the treatment. For example, although
TNF can impair Treg function and Tregs were found to regain suppressor function
following anti-TNF treatment, it cannot be definitively concluded that Tregs directly
ameliorate disease.

Anti-TNF is by no means a universal treatment as approximate 20-40% of antiTNF recipients do not show initial responses and some patients do not maintain longterm responses to treatment (Lipsky et al. 2000, Feldmann 2002). In the next sections,
we describe additional therapies that have been developed for the treatment of arthritis.
17

B. Anti-B cell

Anti-B cell reagents, namely anti-CD20 or rituximab, have gained momentum as
many RA patients (upwards of ~80%) have also demonstrated clinical response to this
treatment (Edwards et al. 2004, Higashida et al. 2005, Cohen et al. 2006). Notably,
many of the trials that have been conducted with anti-B cell therapies were with patients
that showed inadequate response to anti-TNF, suggesting that different pathways of
pathogenesis exist among individuals. Treatment with rituximab results in the depletion
of B cells that express CD20; since long-lived plasma cells have lost this marker, they
are unaffected by this treatment (Edwards et al. 2004, Higashida et al. 2005, Cohen et
al. 2006). However, anti-CD20 treatment has been shown to significantly reduce RF and
anti-CCP levels in some patients, suggesting that these autoantibodies are presumably
produced by CD20 expressing short-lived plasma cells (Edwards et al. 2004, Higashida
et al. 2005, Cohen et al. 2006, Townsend et al. 2010). Interestingly, one study has
reported that the reappearance of these autoantibodies in the serum correlates with
disease relapse (Cambridge et al. 2003). This may suggest that autoantibodies
participate as the dominant pathogenic mechanism in RA. However, some argue that
because the reduction of autoantibodies is not requisite for a clinical response and
because RF and anti-CCP are not completely eliminated in treatment-responsive
patients, B cells may contribute to arthritis development independently of autoantibody
production, possibly as serving as APCs for pathogenic CD4+ T cells.
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C. Others:

Other treatments available for RA are ones that block T cell co-stimulation
(CTLA4-Ig), an IL-1 receptor antagonist (anakinra), an IL-6R blocking antibody (MRA)
and an anti-IL-17 antibody (LY2439821) (Cohen et al. 2002, Moreland et al. 2002,
Nishimoto et al. 2004, Genovese et al. 2010). Less is known about the efficacy of these
treatments but they appear promising.

1.3.5. Summary of inflammatory arthritis in humans

Autoimmune diseases result from a breakdown in self-tolerance but the etiology
of these diseases is still unclear and may differ between individuals. Autoimmune
settings in which inflammatory arthritis develops are associated with activated CD4+ T
cells, autoantibody production and increased levels of several pro-inflammatory
cytokines, indicating that multiple cellular and soluble factors are involved in disease
pathogenesis. However, treatments targeting possible disease mediators (anti-TNF and
anti-B cell) has demonstrated that each treatment is effective, but only in subsets of
patients. This suggest that pathways central to disease may differ between individuals.
It is currently not known why some patients respond to a treatment while others fail to
respond, and there are currently no reliable predictors of response. This leaves us with
the following questions: What are the mechanisms that determine which pathways are
involved? What underlies the heterogeneity in response? Is it because different selfantigens are being recognized in different patients? Several possible target
autoantigens in inflammatory arthritis have been proposed (such as RF and citrullinated
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proteins) (Bennett et al. 2003, Trouw and Mahler 2012). This is because antibodies
directed toward these self-antigens can be found at increased concentrations in
diseased patients relative to healthy individuals. Nonetheless, these findings in human
patients only correlate with disease and cannot directly implicate them in eliciting
disease. Because only correlations can be made in humans, the field has turned to
mouse models of inflammatory arthritis to better assess mechanisms of disease
pathogenesis.

1.4 Mouse models of inflammatory arthritis

Several mouse models of inflammatory arthritis exist, each unique with regard to
how disease initiates as well as the effector pathways involved. This demonstrates that
many distinct, non-overlapping pathways can lead to inflammatory arthritis.

1.4.1 Overexpression/enhanced signaling of cytokines

A key feature of RA is the highly inflammatory nature of the disease, as
compared to osteoarthritis (also a joint disease but believed to be caused by mechanical
stress rather than an autoimmune reaction) (Farahat et al. 1993, Hampel et al. 2013).
Not only are high levels of multiple inflammatory cytokines found directly in the inflamed
joint, but elevated levels of cytokines are also detected in the serum of RA patients
(Steiner et al. 1999, Ziolkowska et al. 2000, McInnes and Schett 2011, Metawi et al.
2011). Indeed, transgenic mice generated to overexpress some prominent inflammatory
cytokines found in human RA develop chronic and erosive arthritis.
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A. hTNF transgenic

Mice generated with a gene construct encoding human TNF lacking a 3’
untranslated region (demonstrated to repress translation of the cytokine) overexpress
TNF systemically and develop chronic polyarthritis (Keffer et al. 1991). Joints of hTNF
transgenic mice exhibit synovial hyperplasia, inflammatory infiltrates, pannus formation,
and cartilage and bone erosion, which closely resembles the human disease.
Monoclonal antibodies directed against human TNF completely prevented arthritis onset
in these mice, establishing the direct role of TNF in driving joint inflammation. As
previously described, TNF has been shown capable of inducing and synergizing with IL1 and IL-6 within arthritic joints (Brennan et al. 1989, Alvaro-Gracia et al. 1991).
Therefore, the relationship and contribution of IL-1 and IL-6 have also been explored in
this model. Arthritis development was significantly attenuated in hTNF transgenic mice
either treated with a neutralizing antibody to IL-1 receptor or crossed with IL-1-/- mice,
demonstrating that IL-1 is an important downstream mediator of TNF for disease
pathogenesis (Probert et al. 1995, Zwerina et al. 2007). IL-6, on the other hand, did not
appear required in this system since disease develops similarly in IL-6 sufficient and IL-6
deficient hTNF transgenic mice (Alonzi et al. 1998). Moreover, the adaptive immune
system was found to not be required in these mice as TNF mediated arthritis is still able
to develop on the RAG-/- background, demonstrating instead the requirement for TNF
production and uptake by innate immune cells (Kollias et al. 1999).
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B. hIL-1 transgenic

Due to the perceived involvement of IL-1 during the development of inflammatory
arthritis, hIL-1 transgenic mice were generated (Niki et al. 2001). Serum from hIL-1
transgenic mice contained high levels of hIL-1 and hIL-1 mRNA was expressed in
multiple tissues, including the joints. Similar to hTNF transgenic mice, hIL-1 transgenic
mice also develop chronic polyarthritis with evidence of synovial hyperplasia, synovitis
and articular degeneration. Thus, overexpression of IL-1 was also sufficient to induce
the development of inflammatory arthritis.

C. gp130F759/F759 mice

Mice generated with a homozygous point mutation in the gp130 subunit of the IL6 receptor exhibit enhanced STAT3 signaling (downstream of the IL-6R) and develop
chronic and erosive arthritis (Atsumi et al. 2002). Arthritic gp130 mice contained
elevated levels of autoantibodies as well as highly activated CD4+ and CD8+ T cells,
implicating the involvement of the adaptive immune system in the disease process.
Indeed, arthritis development is dependent on lymphocytes in this model as gp130 mice
crossed onto a RAG-/- background do not develop disease. Further studies in this
model, however, revealed that CD4+ T cells, but not CD8+ T cells or B cells, are the
subset of lymphocytes required for disease progression in this system (Sawa et al.
2006). Excess IL-6 signaling in gp130 mice induces IL-7 production and subsequent
homeostatic proliferation of CD4+ T cells which then acquire an activated phenotype and
differentiate into arthritogenic Th17 cells (Sawa et al. 2006, Nishihara et al. 2007, Ogura
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et al. 2008). Moreover, not only does IL-6 function to generate pathogenic Th17 cells in
this system, it appears that IL-6 is also a critical downstream target of IL-17; these two
processes together form a positive-feedback loop necessary to sustain inflammation and
drive arthritis development (Ogura et al. 2008).

Notably, work in this model system performed by Murakami et. al. demonstrate
that CD4+ T cell recognition of a joint-specific antigen is not required for arthritis
development, however, accumulation of effector Th17 cells (irrespective of antigen
specificity) directly in the joints is required (Murakami et al. 2011). Even direct injection
of IL-17 into joints of gp130 mice (but not wild type mice) can induce the rapid onset of
arthritis. Arthritis was originally described to develop in gp130 mice beginning around 8
months of age, whereas exogenous IL-17 can induce swollen joints as early as 3 days
after injection (Atsumi et al. 2002, Murakami et al. 2011). These results implicate that
non-antigen-specific activation of the IL-6 amplification loop is sufficient to elicit a jointtargeted disease.

1.4.2 Adjuvant induced models

The previous section demonstrated that overexpression/enhanced signaling of
prominent pro-inflammatory cytokines found in RA was sufficient to elicit spontaneous
inflammatory arthritis in mice. However, it is unclear from these models how the
production of these cytokines can be elicited in a physiological (non-transgenic) setting.
Mouse models of adjuvant induced arthritis allow for the investigation of this aspect,
among others, of disease development.
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A. Collagen induced arthritis (CIA)

CIA is one of the most widely used models for the study of inflammatory arthritis.
This inducible model involves immunization of rats or mice with heterologous type II
collagen (usually chicken or bovine) mixed with complete Freud’s adjuvant (Trentham et
al. 1977). First and foremost, CIA recapitulates the clinical aspects of inflammatory
arthritis in humans – synovial hyperplasia, synovitis, pannus formation and articular
degeneration. Secondly, CIA recapitulates several inflammatory processes and
pathways observed during arthritis development in humans. Notably, CIA susceptibility
is limited to mice bearing certain MHCII alleles (Trentham et al. 1977, Griffiths et al.
1994, Myers et al. 1997), highlighting the existence of arthritogenic CD4+ T cell clones in
a given mouse’s T cell repertoire and also the central role for CD4+ T cells in the disease
process. Findings using this model system illustrate that under steady state conditions,
autoreactive CD4+ T cells (that are indeed present) are maintained tolerant. However,
TCR stimulation of type II collagen-specific CD4+ T cells in the presence of adjuvant
allows for the break tolerance and the subsequent development of arthritis. Disease
pathogenesis in CIA has both a T cell and B cell component: CD4+ T cells isolated from
CIA mice can transfer disease to naïve recipients (Kadowaki et al. 1994) and disease
can be passively transferred by serum antibodies isolated from arthritic CIA mice (Stuart
and Dixon 1983, Wooley et al. 1984). Disease induced by these methods, however, is
not chronic and resides after a few days. The inflammatory cytokines TNF, IL-1, IL-6
and IL-17 have all been shown to play important roles in the development of CIA (Myers
et al. 1997, Alonzi et al. 1998, Lubberts et al. 2001, Nakae et al. 2003).
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Overall, CIA represents a model of inflammatory arthritis that resembles human
arthritis in its clinical appearance and inflammatory pathogenic processes. Disease
development in this model, however, is specifically triggered by heterologous type II
collagen in the context of a strong, TLR stimulus (CFA). How well this translates into
how arthritis initiates in humans is unclear, but non-concordance of arthritis development
in monozygotic twins has led to speculations on the involvement of environmental
factors, such as pathogens, as triggers for autoimmunity.

B. Proteoglycan induced arthritis (PGIA)

PGIA, a second inducible model of inflammatory arthritis, was established
through the injection of human cartilage proteoglycan (PG) with adjuvant into genetically
susceptible mice (Banerjee et al. 1992). This model was developed to assess PG as a
potential autoantigen in human inflammatory arthritis, aside from type II collagen. An
apparent difference between CIA and PGIA is that a single immunization can induce CIA
but PGIA requires several immunizations over a course of a month to a month and a half
to induce disease (Banerjee et al. 1992, O'Neill et al. 2005). Early studies in this system
revealed that CD4+ but not CD8+ T cells are essential for disease induction (Banerjee et
al. 1992). Later studies demonstrated that disease development in this system is also
significantly dependent on B cells, which appear to serve as both APCs and as a source
of pathogenic autoantibodies (O'Neill et al. 2005, Hamel et al. 2008). Furthermore,
disease can be transferred with spleen and lymph node (LN) cells isolated from arthritic
mice, however, successful transfer of disease requires both T and B cells (Mikecz et al.
1990). Interestingly, the inflammatory cytokine IFN-, but not IL-17, was shown to play a
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significant role in PGIA (Doodes et al. 2008). This result is the opposite of what was
found in the CIA mouse model (Vermeire et al. 1997, Lubberts et al. 2001, Nakae et al.
2003). Thus, PGIA and CIA share both similarities and differences in the pathways by
which disease develops.

1.4.3. Alterations in cells of the adaptive immune system

Due to the strong association between certain MHCII alleles and the
development of inflammatory arthritis, CD4+ T cells have been implicated to play a
central role in the pathogenesis of disease (Clarke and Vyse 2009, McInnes and Schett
2011). In these next models, CD4+ T cells are uniquely altered, resulting in a loss of
self-tolerance; these models also demonstrate the multiple roles CD4+ T cells can play in
disease development.

A. SKG mice

A spontaneously derived mutation in the signaling domain of ZAP-70 (ZAP70W163C) is the root cause of inflammatory arthritis development in SKG mice (Sakaguchi
et al. 2003). ZAP-70, a protein-tyrosine kinase which associates with the
phosphorylated form of the TCR zeta chain, constitutes a key molecule in TCR signal
transduction (Chan et al. 1992), and T cells containing the ZAP-70W163C mutation display
attenuated TCR signaling, which seems paradoxical to our understanding of how T cells
participate in autoimmunity (Sakaguchi et al. 2003). Extensive studies performed in
SKG mice have yielded some explanations for this. One explanation that has been
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proposed is that attenuated TCR signaling shifts the TCR repertoire of SKG mice to one
that is highly self-reactive. This is because only highly self-specific and self-reactive T
cell clones that can compensate for the TCR signaling defect can survive positive and
negative selection in the thymus to populate the periphery (Sakaguchi et al. 2003,
Tanaka et al. 2010). Once in the periphery, the self-reactivity of the T cells that have
evaded deletion is high enough to drive T cell proliferation in response to a lymphopenic
environment, despite the ZAP-70 mutation (Hirota et al. 2007). In doing so, CD4+ T cells
in SKG mice acquire an activated phenotype and can also differentiate into Th17 cells.
In support of the pathogenic role of CD4+ T cells in this system, adoptive transfer of
CD4+ T cells from SKG mice into RAG-/- mice (B and T cell deficient) is sufficient to elicit
arthritis; this experiment also demonstrates that B cells as an effector population are not
required (Hirota et al. 2007). Importantly, CD4+ T cells from IL-17-/-SKG mice were
incapable of transferring disease (Hirota et al. 2007). This solidified that disease
develops in SKG mice by an IL-17-dependent mechanism, driven by pathogenic Th17
cells that spontaneously form in this setting. An additional and non-mutually exclusive
explanation for why autoimmune arthritis develops in SKG mice is that Treg function in
this system appears impaired (Tanaka et al. 2010). Therefore, elegant studies
performed in this model system have attempted to reconcile the paradox that T cells with
attenuated TCR signaling can lead to the development of autoimmunity and several
convincing explanations have been proposed. Although CD4+ T cells clearly play a
critical role in the development of arthritis in the SKG model, the exact specificities of the
arthritogenic T cells in this system have yet to be elucidated.

Because Th17 cell formation is promoted and IL-17 is required for disease
development in SKG mice (Hirota et al. 2007), studies were performed to elucidate the
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mechanism by which this occurs. IL-6 appears required in this process as IL-6-/- SKG
CD4+ T cells transferred into IL-6-/- RAG-/- mice failed to develop into Th17 cells and also
failed to initiate disease (Hirota et al. 2007). Furthermore, a following report
demonstrated that upregulated CCL20 expression by synoviocytes actively recruits Th17
cells (through their expression of CCR6 – the receptor for CCL20) to the joints (Hirota et
al. 2007). TNF, IL-1B and IL-17 were all shown capable of upregulating synoviocyte
expression of CCL20. An anti-CCR6 blocking mAb, however, only moderately
attenuated disease development.

An interesting feature of the SKG model is that arthritis only develops in mice
housed in non-specific pathogen free (non-SPF) conditions, demonstrating that microbes
(especially fungi) are necessary to provoke the development of arthritis in this system
(Yoshitomi et al. 2005). Moreover, injections of zymosan or laminarin selectively
promote the expansion/differentiation of Th17 cells (and not Th1 cells) in SKG mice
(Hirota et al. 2007). Collectively, these finding argue that fungal products prime and
activate innate immune cells/APCs which are capable of promoting arthritogenic Th17
cells in SKG mice.

Strikingly, effects on T cell selection and the spectrum of autoimmune
manifestations that occur in SKG mice can be modulated by varying the number of
mutated ZAP-70 alleles (Tanaka et al. 2010). Amazingly, these results demonstrate that
the degree with which TCR signaling is altered can dramatically affect not only T cell
development but also autoimmune disease manifestations in a gene dosage dependent
manner. In support of this, Siggs et. al. produced similar findings in a separate ZAP-70
mutant model (Siggs et al. 2007). Mice with varying degrees of TCR attenuation were
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analyzed and compared. Again, the extent of T cell deletion and of T cell activation was
affected in a gene dosage dependent manner; the effect of TCR signal strength on
autoimmune manifestations was not evaluated in this study. These studies begin to
demonstrate that variations in the CD4+ T cell response to self-antigen(s) can indeed
influence the degree of systemic immune activation and its outcome on autoimmune
disease development.

B. K/BxN mice

This next mouse model of inflammatory arthritis was generated through mating
the KRN TCR transgenic mouse with a non-obese diabetic (NOD) mouse and was
named K/BxN mice (Kouskoff et al. 1996). The KRN TCR was originally known to
recognize a peptide of bovine ribonuclease, when presented by MHCII I-Ak. However, in
a NOD background, it was discovered that KRN T cells recognize the systemically
distributed protein - glucose-6-phosphate isomerase (GPI), complexed with the I-Ag7
MHCII molecule as a target autoantigen, the end result being the spontaneous
development of inflammatory arthritis in K/BxN mice. The importance of CD4+ T cells in
K/BxN mice is evident since a TCR transgenic mouse was used to generate this model
system. Unlike in the SKG model, the main role CD4+ T cells serve in this system
appears to be as help for B cells to develop into plasma cells capable of secreting
pathogenic autoantibodies since serum isolated from arthritic K/BxN mice rapidly
induces disease (within 2-3 days) following transfer into naïve BALB/c recipients
(Korganow et al. 1999). Joint swelling in serum recipients, however, is transient, often
resolving after approximately 3 weeks; this suggests that constant production of the
arthritogenic autoantibody is required for disease persistence. The mechanism by which
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this occurs has been studied extensively, solidifying that autoantibodies represent a
principle effector mechanism in K/BxN mice. Briefly, it has been proposed that
arthritogenic anti-GPI autoantibodies that develop in this system preferentially deposit
and accumulate along the surface of cartilage in the joints, despite the ubiquitous
expression of GPI, triggering an inflammatory complement cascade and ultimately joint
destruction (Matsumoto et al. 2002).

Cytokines also significantly contribute to the effector phase of disease
development in this model system. Therefore, serum transfers were performed in
cytokine deficient mice and disease was assessed. IL-6 did not appear required but IL-1
was essential for K/BxN serum induced arthritis (Ji et al. 2002). Anti-IL-17 treatment
was also found to completely prevent disease development in K/BxN mice (Wu et al.
2010). The contribution of TNF less clear cut – the majority, but not all, of TNF-/recipient mice were protected from developing passively transferred arthritis,
demonstrating that TNF plays a significant, but not an indispensible, role in this model
system (Ji et al. 2002). Why this variability was observed in a seemingly uniform
experiment (same serum transfer protocol into inbred TNF-/- mice) is unclear, however,
the authors suggest this variability could be due to unknown stochastic/environmental
factors. Interestingly, these results are somewhat evocative of the unequal response of
RA patient to anti-TNF therapy.

Strikingly, disease was significantly attenuated in K/BxN mice housed in germ
free (GF) conditions, demonstrating that commensal microbes (and specifically
segmented filamentous bacteria (SFB)) play a significant role in the development of
arthritis in this system (Wu et al. 2010). Notably, anti-GPI titers and Th17 cell
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frequencies were significantly reduced in germ free K/BxN mice relative to SPF K/BxN
mice. Moreover, it was discovered that anti-IL-17 treatment and elimination of IL-17R
expression specifically on B cells significantly reduced germinal center formation.
Therefore from these data, the authors suggest that the contribution of commensals in
the development of arthritis in K/BxN mice was to promote Th17 cell formation which in
turn support germinal centers needed for the production of arthritogenic autoantibodies.

The K/BxN model of inflammatory arthritis has provided insight on how CD4+ T
cell recognition of a ubiquitous autoantigen, the specificities of which are known, can
promote a joint-targeted disease elicited by autoantibodies.

1.4.4 Summary on mouse models of inflammatory arthritis

The diversity of mouse models capable of recapitulating some aspects of human
arthritis demonstrate that multiple, possibly disparate, pathways can lead to the
development of arthritis. Although these mouse models are not completely
representative of the processes that occur during inflammatory arthritis in humans, they
have allowed certain aspects of the disease to be studied more carefully. The findings
from mouse models demonstrate not only how inflammatory cytokines can lead to a
joint-targeted disease but that they can work in interconnecting networks to promote
arthritis development; they exemplify the central yet diverse roles CD4+ T cells can play
during the development of autoimmune arthritis; and they demonstrate that the extent to
which B cells and autoantibodies contribute to disease pathogenesis appears to vary
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depending on the model system under evaluation. Several of the models further
implicate a role for microbes for disease initiation (CIA, PGIA, SKG and K/BxN).

1.5 TS1xHACII: a spontaneous mouse model of inflammatory arthritis

TS1 mice express a transgenic TCR that is specific for the I-Ed-restricted S1
determinant of influenza virus A/PR/8/34 (PR8) hemagglutinin (HA); clonotypic T cells
can be identified by the monoclonal antibody, 6.5 (Kirberg et al. 1994). HACII mice
express the PR8 HA as a surrogate self-antigen under the control of an MHCII promoter,
which directs the expression of HA to APCs (Reed et al. 2003). When TS1 mice are
mated with HACII mice, both the TS1 TCR transgene and the PR8 HA are co-expressed
in their progeny: TS1xHACII mice. As previously described, the majority of TS1xHACII
mice spontaneously develop inflammatory arthritis which first becomes evident between
6-8 weeks of age (Rankin et al. 2008).

In the thymii of TS1xHACII mice, CD4+ T cells bearing the clonotypic TCR
(6.5+CD4+) recognize the S1 self-antigen with high affinity and are subjected to extensive
thymic deletion ((Rankin et al. 2008) and Fig. 1-1). However, central tolerance is
incomplete as we can find a small population of 6.5+CD4+ T cells in both the LNs and
spleens of young, pre-arthritic TS1xHACII mice. These high affinity, autoreactive
6.5+CD4+ T cells then interact with HA-expressing APCs, leading to the reciprocal
activation of both T cells and APCs. Activated B cells proceed to differentiate into
plasma cells and secrete high levels of IgG. However, B cells appear unnecessary for
disease as B cell deficient TS1xHACII.JH-/- mice were found to develop arthritis (Rankin
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et al. 2008). The T cell-APC interaction in TS1xHACII mice was also demonstrated to
promote the development of Th17-trophic inflammatory monocytes which may be one
way by which Th17 cells form in this system (Simons et al. 2013). Indeed, arthritis in this
system develops by an IL-17-dependent mechanism as blockade of this cytokine
significantly blocks disease onset (Oh et al. 2012). Importantly, TS1xHACII mice on a
RAG deficient background can develop arthritis, demonstrating that other TCR
specificities besides the TS1 TCR are not necessary to initiate disease (Rankin et al.
2008).

Notably, TS1xHACII mice develop disease in the presence of high frequencies of
Tregs (Oh et al. 2012). Provision of exogenously derived HA-specific Tregs was unable
to ameliorate disease, but Tregs from BALB/c mice (with a polyclonal TCR repertoire)
could. Furthermore, suppression of disease with polyclonal Tregs was associated with
significantly reduced Th17 cell frequencies.

Thus, in TS1xHACII mice, both the target antigen and disease-eliciting T cell
specificity are known and several factors involved in disease pathogenesis have been
elucidated. Therefore, manipulation of the TS1xHACII mouse model of arthritis will allow
us to explore how altering CD4+ T cell recognition of the target antigen can affect
disease development.
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Chapter 2: Materials and Methods

2.1 Transgenic mice
TS1 mice express a transgenic TCR (V4, V8.1/8.2) that is specific for the S1
determinant of influenza virus A/PR/8/34 (PR8) HA presented by MHC class II I-Ed.
Clonotypic cells can be identified by the monoclonal antibody 6.5 (Kirberg et al. 1994).
TS1(SW) mice express a transgenic TCR (V8.3, V10) that is specific for an analog of
the PR8 S1 peptide that is derived from the influenza virus A/SW/33 (SW) HA (Cerasoli
et al. 1995, Cerasoli et al. 1995). HACII mice express the full length PR8 HA transgene
driven by an MHC class II I-E promoter (Reed et al. 2003).

To generate TS1xHACII.JH-/- and TS1(SW)xHACII.JH-/- mice: TS1, TS1(SW)
and HACII mice were first bred to JH-/- mice (Chen et al. 1993) on the BALB/c
background and then TS1.JH-/- mice or TS1(SW).JH-/- mice were mated with HACII.JH-/mice. All JH-/- mice were screened for the absence of B cells by flow cytometry.

Arthritic mice and aged-matched control mice were analyzed between 15-24
weeks of age. All mice have been backcrossed with BALB/c mice for at least 10
generations and are maintained on this background. BALB/c mice were purchased from
Charles River Laboratories. All mice were housed in The Wistar Institute Animal Facility
under specific pathogen-free conditions. All experiments were performed according to
protocols approved by The Wistar Institutional Animal Care and Use Committee.
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2.2 Genotyping of transgenic mice
TS1, TS1(SW) and HACII transgenic mice were genotyped upon weaning at 3 to
4 weeks of age. Tail samples (~2 mm) were digested overnight in 200 L of tail lysis
buffer at 55oC. Digestion was stopped by heat inactivation at 95oC (10 minutes).
Samples were then used as template DNA for PCR. PCR was performed in 50 L
reactions: 5 L 10X PCR amplification buffer, 50 ng of appropriate primers, 2 L of 5
mM dNTPs, 1 unit of Taq polymerase, and 3 L of tail DNA. PCR reactions were run in
a thermocycler for 35 cycles, with each cycle consisting of a 1 minute annealing period
at 50oC (for HA transgene tests) and 65oC (for TCR transgene tests), a 2 minute
elongation period at 72oC, and a 1 minute denaturation period at 94oC. An additional
annealing and elongation step was performed before ending the amplification cycles.
PCR products were visualized on a 1% agarose gel containing ethidium bromide.

The primers used for genotyping were purchased from Integrated DNA
Technologies (Coralville, IA) and their sequences are as follows:

HA
HA uni-5’

5’- CCA GCA GAT TTC ATC GAC TAT G -3’

HA uni-3’

5’- CCA GTA ATA GTT CAT CCT CCC -3’

TS1
V2.1 CDR3

5’- GAA CTG CTC AGC ATA ACT CCC -3’

VCROSS5’

5’- GAG GCT GCA GTC ACC CAA AG -3’
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TS1(SW)
TS1K  JUNCTION

5’- CTC AGC ACC CCT GCC AGC CTG -3’

TS1K  Vgene

5’- ATG GGC TGT AGG CTC CTA AGC -3’

2.3 Assessment of arthritis

Mice were assessed weekly for signs of arthritis. All four paws were analyzed for
swelling by a blinded examiner, and each paw was assigned a score: 0, no visible
swelling or discoloration; 1, visible swelling with/without discoloration; 2, severe swelling
accompanied by skin discoloration. The minimum score per mouse is 0 and the
maximum score per mouse is 8 (a combined score if all four limbs scored a 2).

2.4 Histology
Limbs, heart, kidneys, intestines (flushed with PBS) and lungs (perfused with
formalin) were fixed in 10% formalin (Globe Scientific, Inc.). Limbs were decalcified and
all tissues were then embedded in paraffin and cut at ~5 microns to generate sections,
which were stained with H&E. Blinded pathological scoring of sections was performed.
Grading scale: 0=not present, 1=minimal, 2=mild, 3=moderate, 4=marked.

2.5 Flow cytometry and cell sorting
Single-cell suspensions of joint-draining lymph nodes (jdLNs) (pooled axillary,
brachial, and popliteal LNs), spleens, thymii or joints were stained with the Live/Dead
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Fixable Aqua Dead Cell Stain Kit from Invitrogen (except when sorting) and then for
surface markers at 4oC for 30 minutes. 1 x 106 to 3 x 106 cells were plated in 96-well V
bottom plates and stained with antibodies diluted in 100 L of FACS buffer. The
following Abs were purchased from eBioscience or BD Pharmingen: anti-B220 (RA36B2), anti-CD3 (145-2C11), anti-CD4 (RM4-5), anti-CD8 (53-6.7), anti-CD11b (M1/70),
anti-CD11c (N418), anti-CD19 (1D3), anti-CD25 (PC61.5), anti-CD44 (IM7), anti-CD45
(30-F11), anti-CD62L (MEL-14), anti-CD69 (H1.2F3), anti-CD138 (281-2), anti-Fas
(Jo2), anti-Foxp3 (FJK-16s), anti-Gr-1 (RB6-8C5), anti-IFN- (XMG1.2), anti-IgD (1126c), anti-IL-17 (eBio17B7), anti-IL-17RA (PAJ-17R), anti-MHCII (M5/114.15.2), and
anti-V10 (B21.5). Anti-6.5-biotin (Kirberg et al. 1994) and anti-V8.3-biotin (KT50, BD
Pharmingen) were detected with streptavidin-Qdot655 (Invitrogen). Intracellular Foxp3
staining was performed according to the eBioscience protocol. Samples were collected
on the LSR II flow cytometer (BD Biosciences) and data were analyzed using FlowJo
software (Tree Star). Cells were sorted for use in in vitro assays on a MoFlow
(DakoCytomation) or FACSAria (BD Biosciences) cell sorter and populations obtained
were of ~95% purity.

2.6 Intracellular cytokine staining
Cells were stimulated in supplemented Iscove’s Modified Dulbecco’s Medium
(IMDM) plus 10% FBS with 50 ng/mL PMA (Sigma-Aldrich), 1 M ionomycin (SigmaAldrich), and a 1:1000 dilution of brefeldin A (eBioscience) for 4 hours at 37oC.
Following staining for surface markers, cells were fixed and permeabilized using the
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Foxp3 Buffer Set (eBioscience) according to the manufacturer’s protocol and then
intracellular cytokine staining was performed.

2.7 Isolation of cells from the joints
Paws from all four limbs of a mouse were isolated by dissection and fingers/toes
were excised. Skin was removed from around these distal joints before incubation in 5
mL of a digestion solution consisting of 400 U/mL collagenase D (Roche) and 0.2 mg/mL
DNase I (Roche) in PBS with calcium and magnesium at 37oC for 1 hour in a petri dish.
Joints were then manually disrupted through a 70 m cell strainer (BD Falcon) and these
single-cell suspensions were analyzed by flow cytometry.

2.8 Labeling of cells with cell proliferation tracing dyes
For CFSE (Invitrogen) labeling: Cells to be labeled were resuspended at 1 x 107
cells/mL in sterile, serum-free 1X Dulbecco’s Phosphate-Buffered Saline (DPBS) without
calcium & magnesium (Mediatech, Inc.). A 5 mM stock solution of CFSE was prepared
and added at a 1:1000 dilution to the cell suspension. Cells were incubated with CFSE
at room temperature for 3.5 to 4 minutes. CFSE-labeling was then quenched with an
equal volume of FBS at the end of the incubation period. For CellTrace Violet (CTV;
Invitrogen) labeling: Manufacturer’s protocol was followed to label cells with CTV.
Following either CFSE or CTV labeling, cells were washed at least twice with
supplemented IMDM with 10% FBS before use in in vitro cultures.
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2.9 In vitro proliferation assays
To assess TCR reactivity toward S1 (SFERFEIFPKE) and S1(SW)
(SFEKFEIFPKT) peptides, CFSE-labeled LN cells from TS1 or TS1(SW) mice (5 x 104
cells/well) were co-cultured with BALB/c splenocytes as APCs (5 x 105 cells /well) in
supplemented IMDM plus 10% FBS with or without peptide at various dilutions. After 3
days, cells were analyzed by flow cytometry for CFSE dilution. To assess CD4+ T cell
reactivity in an autologous mixed lymphocyte reaction, T cells (sorted as CD4+CD8cells) from TS1xHACII or TS1(SW)xHACII mice were CFSE-labeled and cocultured with
APCs (sorted as CD3- cells) isolated from the same mouse, from HACII mice, or from
BALB/c mice; each population was plated at the same numbers of cells/well as above.
Anti-CD3 (145-2C11, NA/LE, BD Pharmingen) (0.1 µg/mL) was added to some wells as
a positive control. After 3 days, cells were analyzed by flow cytometry for CFSE dilution.

2.10 In vitro suppression assay
CD4+CD25hi regulatory T cells (Tregs) were purified by cell sorting from spleens
of non-arthritic anti-TNF treated TS1xHACII, arthritic isotype control-treated TS1xHACII,
or BALB/c mice, and cocultured in varying numbers with 5 x 104 CTV-labeled
(Invitrogen) CD4+CD25- responder T cells isolated from spleens of TS1xHACII mice and
2 x 105 CD3- splenocytes from BALB/c mice (as APCs) in supplemented IMDM plus 10%
FBS in 96-well U-bottom plates. Similarly, Tregs were sorted from spleens of nonarthritic anti-TNF treated TS1(SW)xHACII, arthritic isotype control-treated
TS1(SW)xHACII, or BALB/c mice, and cocultured with CTV-labeled responder T cells
isolated from spleens of TS1(SW)xHACII mice and BALB/c APCs. To stimulate both
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responder cells and Tregs, anti-CD3 was added at 0.15 µg/mL. After 3 days of culture,
cells were analyzed by flow cytometry for CTV dilution. Percent inhibition was
determined as: (1 – (% divided cells in each responder cells and Tregs coculture/%
divided cells in responder cells only culture)) x 100.

2.11 In vivo antibody treatments
For anti-IL-17R treatment, mice were injected i.p. with 0.5 mg of either rat antimouse IL-17R blocking Ab (M751, provided by Amgen) or an isotype control Ab (MOPC21, BioXCell) weekly from 5-14 weeks of age. For anti-CD20 treatment, mice were
injected i.v. with 0.25 mg of either anti-mouse CD20 depleting Ab (18B12, provided by
Biogen Idec) or an isotype control Ab (2B8, anti-human CD20 with no cross-reactivity to
mouse CD20, provided by Biogen Idec) once every 3 weeks from 5-14 weeks of age
(Hamel et al. 2008). For anti-TNF treatment, mice were injected i.p. with 0.5 mg of either
rat anti-mouse TNF- neutralizing Ab (XT3.11, BioXCell) or an isotype control Ab
(HRPN, BioXCell) weekly from 5-14 weeks of age.

2.12 ELISAs for antibodies
Concentrations of total IgG in the serum were determined using U-bottom vinyl
plates (Costar) that were coated with goat anti-mouse Ig (H+L) (SouthernBiotech), and
bound Abs were detected with goat anti-mouse IgG-alkaline phosphatase
(SouthernBiotech). Purified mouse IgG (SouthernBiotech) was used as a standard. To
detect rheumatoid factor, plates were coated with purified mouse IgG1, lambda (BD
Pharmingen), and bound Abs were detected with rat anti-mouse kappa light chain-biotin
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(SouthernBiotech) followed by streptavidin-alkaline phosphatase. Anti-type II collagen,
anti-CCP and anti-dsDNA titers were determined using the anti-mouse Type II Collagen
IgG (Chondrex, Inc.), QUANTA Lite CCP3 IgG (INOVA Diagnostics, Inc.), or mouse antidsDNA total Ig (Alpha Diagnostic International) ELISA kits, respectively, according to the
manufacturer’s instructions.

2.13 Luminex assays for serum cytokines
Serum samples were analyzed on MILLIPLEX MAP Mouse Cytokine/Chemokine
luminex assay kits (Millipore) by the University of Pennsylvania Human Immunology
Core.

2.14 Serum transfers
Blood from donor mice was collected by heart puncture post-mortem and was
allowed to coagulate for at least one hour at room temperature before centrifugation in
order to isolate the serum fraction of the blood. Each recipient mouse was injected i.p.
with 150 µL of donor serum on day 0 and was boosted with 100 µL of donor serum on
day 3. Recipient mice were monitored for arthritis development every 3-4 days for 3
weeks.
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2.15 Statistics
Statistical analyses were performed using Fisher’s Exact test, Mann-Whitney test
or one-way ANOVA with Tukey post-test, as appropriate, with GraphPad Prism software
(GraphPad). P values less than 0.05 were considered significant.
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Chapter 3: CD4 T cell affinity influences inflammatory arthritis development and
extent of systemic immune activation

3.1 Introduction

The contribution of CD4+ T cells to the development of inflammatory arthritis has
long been implicated as susceptibility to arthritis is strongly linked to certain MHC class II
alleles (Clarke and Vyse 2009, McInnes and Schett 2011). Moreover, activated effector
CD4+ T cells can be found in inflamed, arthritic joints and treatments designed to block
CD4+ T cell co-stimulation has shown efficacy in some RA patients (Moreland et al.
2002). In mice, it has been demonstrated that an increased precursor frequency of
CD4+ T cells specific for a known autoantigen (through the use of TCR transgenic mice),
such as in K/BxN and TS1xHACII mice, and alterations to TCR signaling, such as in
SKG mice, could promote autoimmune arthritis (Kouskoff et al. 1996, Sakaguchi et al.
2003). Also, in models where arthritis is induced (CIA and PGIA), susceptibility is
associated with certain MHCII alleles (Trentham et al. 1977, Griffiths et al. 1994, Myers
et al. 1997). Therefore, it has been appreciated that CD4+ T cells can play a major role
in driving autoimmune arthritis.

But how CD4+ T cells recognize self-antigen and how this in turn affects the
attributes of systemic immune activation and the outcomes of disease development is
poorly understood. This is particularly difficult to assess in human patients as the selfantigens that are recognized by autoreactive CD4+ T cells are not well characterized
(Bennett et al. 2003, Trouw and Mahler 2012). Several candidate autoantigens,
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however, have been proposed, including type II collagen, IgG Fc and citrullinated
proteins. Of note, several of the possible target autoantigens identified in humans so far
are not joint-specific but rather ubiquitously expressed. Support of systemically
expressed autoantigens as targets for autoreactive CD4+ T cells has been demonstrated
in the aforementioned mouse models of arthritis. Developed in and previously described
by our lab, the TS1xHACII spontaneous mouse model of inflammatory arthritis is a
system whereby the systemic expression of an ectopic antigen in addition to the coexpression of a CD4+ TCR transgene for that antigen results in arthritis development
(Rankin et al. 2008). Notable features of TS1xHACII mice are that the majority of mice
develop arthritis and that the TCR transgene expressed recognizes the target selfantigen as a high affinity, cognate antigen. Therefore, we investigated how self-antigens
are being recognized by autoreactive CD4+ T cells during autoimmune arthritis, and
more specifically, how can the affinity of autoreactive CD4+ T cells for a target selfantigen affect disease development.

For this purpose, we modified the TS1xHACII model system by crossing the
same antigen expressing mouse used in the TS1xHACII system with a mouse
expressing a lower affinity TCR for the target self-antigen, generating TS1(SW)xHACII
mice. We show here that lowering the affinity of an autoreactive TCR for a single target
antigen was able to significantly modulate disease development. Significantly fewer
male TS1(SW)xHACII mice developed arthritis in comparison to female TS1(SW)xHACII
mice and to male TS1xHACII mice, but females from both strains developed arthritis with
similar penetrance. Also, we found evidence of extra-articular manifestations of disease
in arthritic TS1xHACII mice but this was rarely observed in arthritic TS1(SW)xHACII
mice. The affinity with which CD4+ T cells recognize the target autoantigen in
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TS1xHACII and TS1(SW)xHACII mice not only influenced disease susceptibility but also
appeared to influence the extent of systemic immune activation. TS1xHACII mice
contained CD4+ T cells that displayed a high degree of autoreactivity and high
concentrations of inflammatory cytokines and IgG in the serum. Conversely,
TS1(SW)xHACII mice contained CD4+ T cells that displayed a relatively low degree of
autoreactivity and lower concentrations of cytokines and IgG in the serum. Collectively,
these results demonstrate that an altered CD4+ T cell response to a single target
autoantigen can prominently shape the development of inflammatory arthritis.
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3.2 Results

3.2.1 TS1xHACII mice spontaneously develop autoimmune arthritis with high
penetrance

TS1 mice express a transgenic TCR that is specific for the I-Ed-restricted S1
determinant of PR8 HA (Kirberg et al. 1994). HACII mice express the PR8 HA as a
surrogate self-antigen under the control of an MHCII promoter, which directs the
expression of HA to APCs (Reed et al. 2003). When TS1 mice are mated with HACII
mice, both the TS1 TCR transgene and the PR8 HA are co-expressed in their progeny:
TS1xHACII mice (Fig. 3-1a). As previously described (Rankin et al. 2008, Oh et al.
2012, Simons et al. 2013) and also reported here, TS1xHACII mice spontaneously
develop overtly inflamed fore- and hind-paws, as represented in the photographs in Fig.
3-1b. We did not observe any evidence of inflammation in the paws of TS1 or HACII
mice.

Multiple cohorts of TS1xHACII mice were assessed weekly for the development
of swollen paws and from this, arthritis penetrance (percent of mice that developed at
least 1 inflamed paw) and arthritis severity were determined. We found that arthritis
develops in TS1xHACII mice beginning around 6-8 weeks of age, and it does so with
similar penetrance and kinetics in male and female mice (Fig. 3-1c). Also, at 14 weeks
of age, the combined scores of arthritis severity in all four limbs did not differ significantly
between male and female TS1xHACII mice.
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These results, together with extensive findings previously described in this
mouse model system (Rankin et al. 2008), indicate that the co-expression of the TS1
transgene along with its cognate antigen (PR8 S1) is essential to drive disease
development in TS1xHACII mice as TCR and HA transgene only mice do not develop
disease. This further suggests that the development of CD4+ T cells expressing the TS1
TCR in the presence of their agonist peptide is an important component in the disease
process. Indeed, TS1xHACII mice that have been mated onto a RAG deficient
background also develop spontaneous arthritis (Rankin et al. 2008). Moreover, these
results extend the previous findings by showing that male TS1xHACII mice develop
inflammatory arthritis to the same extent as female TS1xHACII mice.

3.2.2 Affinity of TS1 and TS1(SW) T cells for S1 peptide

Numerous studies in both humans and mice expound on the contribution(s) of
CD4+ T cells in the development of inflammatory arthritis. However, how autoreactive
CD4+ T cells recognize and respond to self-antigens and how this can in turn lead to the
development of autoimmunity is poorly understood (Riley et al. 2000, Siggs et al. 2007).
This question is especially hard to study in human arthritis patients as the self-antigens
recognized by autoreactive CD4+ T cells are not well characterized (Bennett et al. 2003,
Trouw and Mahler 2012). Since a notable feature of TS1xHACII mice is that the TS1
TCR recognizes the S1 self-peptide as a high affinity, cognate antigen (Rankin et al.
2008), we had a unique opportunity to study how changing the affinity with which a TCR
recognizes a known, target antigen could affect disease development. For this purpose,
we utilized TS1(SW) mice, which express a transgenic TCR that was raised against a
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variant influenza virus, called SW virus (Cerasoli et al. 1995, Cerasoli et al. 1995,
Boesteanu et al. 2006). The S1 determinant within the HA protein of SW virus (termed
S1(SW)) is an analog of the PR8 S1 peptide and differs from S1 by two amino acid
residues (Fig. 3-2a). Clonotypic, HA-specific T cells in TS1(SW) mice recognizes
S1(SW) peptide as an agonist and S1 peptide as a partial-agonist. This is demonstrated
here in an in vitro proliferation assay. While CFSE-labeled CD4+ T cells from TS1 mice
proliferated robustly in response to micromolar amounts of S1 peptide (as indicated by
CFSE-dilution in red histograms), T cells from TS1(SW) mice proliferated weakly even to
high amounts (3 uM) of S1 peptide and appeared unresponsive to lower concentrations
of S1 peptide (Fig. 3-2b). This is a reflection of the low intrinsic affinity of the TS1(SW)
TCR for the S1 peptide, because the same CD4+ T cells proliferated robustly upon
exposure to their cognate antigen, S1(SW) peptide (blue histograms). Similarly, when
splenocytes from HACII mice were used as a source of S1 peptide-expressing APCs,
CD4+ T cells from TS1 mice proliferated strongly and TS1(SW) T cells proliferated
weakly in response (Fig. 3-2c).

We next wanted to investigate how TCR affinity for the S1 self-peptide would
affect CD4+ T cell development in TS1xHACII and TS1(SW)xHACII mice. Thymii from
both TS1xHACII and TS1(SW)xHACII mice contained significantly lower frequencies of
clonotypic CD4+ T cells (identified as 6.5+ in mice expressing the TS1 transgene and
V8.3+V10+ in mice expressing the TS1(SW) transgene) compared to TS1 mice
(p=0.0007) and TS1(SW) mice (p=0.0002), respectively (Fig. 3-2d). Notably, the fold
reduction of the frequency of 6.5+CD4+ T cells in TS1xHACII mice (~15 fold) is much
greater than that of V8.3+CD4+ T cells observed in TS1(SW)xHACII mice (~2 fold).
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In line with the our findings from the in vitro proliferation assays performed above, these
data further demonstrate the affinity of the TS1 and TS1(SW) TCR for S1 peptide. The
reduced representation of clonotypic CD4+ T cells in both TS1xHACII and
TS1(SW)xHACII mice is most likely due to thymic deletion because not only were the
percentages of these cells significantly reduced compared to TCR single transgenic
mice but their absolute numbers were significantly reduced as well. Of note, there was
also a significant reduction in the frequency of CD4+CD8- thymocytes in TS1(SW)xHACII
mice when compared to TS1(SW) mice (p=0.0002); the CD4+CD8- population did not
differ between TS1 and TS1xHACII mice. As the TS1(SW) TCR is a better allelic
excluder compared to the TS1 TCR (~75% to ~28%), the deletion of clonotypic T cells in
TS1(SW)xHACII mice, which are largely CD4+, could account for the overall decrease in
CD4+CD8- cells. We also found that CD4+CD8- thymocytes from TS1(SW)xHACII mice
expressed lower levels of V8.3 compared to TS1(SW) mice. Reduced surface
expression of the 6.5 TCR was observed on TS1xHACII CD4+CD8- thymocytes relative
to TS1 thymocytes as well (Rankin et al. 2008). Thus, it is possible that only clonotypic
CD4+CD8- thymocytes with low surface TCR expression are able to escape negative
selection.

Collectively, these data show that the TS1(SW) TCR has a lower affinity for S1
peptide than the TS1 TCR, as demonstrated in in vitro proliferation assays and in the
extent of clonotypic CD4+ T cell deletion in thymii of double transgenic mice.
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3.2.3 TS1(SW)xHACII mice spontaneously develop inflammatory arthritis that is
female biased

To investigate whether an autoreactive TCR with low affinity for the S1 selfpeptide would be able to drive arthritis development, we generated TS1(SW)xHACII
mice by mating TS1(SW) mice with HACII mice (Fig. 3-3a). Despite the lower affinity
TCR, TS1(SW)xHACII mice also developed overtly visible, swollen fore- and hind-paws,
similar to what was observed in TS1xHACII mice (Fig. 3-3b). Again, expression of the
HA-specific TCR and HA together appear essential for disease initiation as TS1(SW)
mice rarely show any indication of joint swelling even at 14 weeks of age (Fig. 3-3c).
When arthritis development was assessed in TS1(SW)xHACII mice over time, we found
that the large majority of female mice developed arthritis by 14 weeks of age, and the
penetrance and severity of arthritis in female TS1(SW)xHACII and female TS1xHACII
mice were comparable (Fig. 3-3d and Fig. 3-1c). Conversely, there was a significant
delay in the development of arthritis in male TS1(SW)xHACII mice, and significantly
fewer male TS1(SW)xHACII mice developed arthritis by 14 weeks of age when
compared to female mice of the same lineage and to male TS1xHACII mice (p=0.007).
Even after one month, arthritis penetrance in male TS1(SW)xHACII mice did not
increase. Moreover, the overall severity scores for male TS1(SW)xHACII mice were
significantly lower than for female TS1(SW)xHACII mice at both 14 and 18 weeks of age.

Collectively, these data demonstrate that recognition of self-antigen by CD4+ T
cells bearing a low affinity TCR is able to drive the development of autoimmune arthritis.
However, in the context of the low affinity TS1(SW) TCR, disease develops with a
pronounced sex bias that was not observed in the high affinity TS1xHACII model.
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3.2.4 Histopathological examination of TS1xHACII and TS1(SW)xHACII mice

We next performed histopathological examinations of joints and tissues from
arthritic TS1xHACII and TS1(SW)xHACII mice, as well as from aged-matched mice
devoid of overt paw swelling (designated as “non-arthritic”). For the analysis of joints,
paws from the various mice were sectioned and stained with H&E. Photographs of
representative hind-paw sections were taken at 4X and 10X magnification (Fig. 3-4a). At
low magnification, the extensive infiltration of immune cells present within the joints of
TS1xHACII and TS1(SW)xHACII mice designated as arthritic (and the absence of such
in control and “non-arthritic” mice) can be visualized. In the high magnification
photographs, distinct areas of cartilage and bone erosion can be observed in sections
from arthritic mice but not in sections from control or “non-arthritic” mice.

Sections from individual mice designated as either arthritic or non-arthritic were
scored (on a scale of 0 – 4, with 4 being the most severe) for synovial hyperplasia,
synovitis and articular degeneration, all of which are characteristic of inflammatory
arthritis (McInnes and Schett 2011). Sections taken from the swollen joints of female
TS1xHACII and TS1(SW)xHACII mice exhibited high degrees of hyperplasia, synovitis
and articular degeneration, and generated significantly higher severity scores than did
sections obtained from control TCR-only mice, supporting their designation as arthritic
(Fig. 3-4b). By contrast, when we examined sections that had been obtained from
TS1(SW)xHACII mice (both male and female) that did not exhibit overt joint swelling, we
found that these sections did not differ from control mice with respect to all three criteria
assessed, supporting and validating their designation as non-arthritic. Moreover, the
synovitis and articular degeneration scores generated from arthritic male
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TS1(SW)xHACII mice were significantly lower than those from arthritic female
TS1xHACII and TS1(SW)xHACII mice, indicating that, in addition to lower disease
penetrance, the severity of arthritis was lower in arthritic male versus arthritic female
mice.

We also examined extra-articular tissues for evidence of inflammation, and as
previously reported, we found extensive perivascular infiltrates in the lungs of arthritic
TS1xHACII mice ((Rankin et al. 2008) and Fig. 3-5a and b)). By contrast, no differences
were observed in the extent of perivascular infiltration in the lungs of either male or
female TS1(SW)xHACII mice and control mice, irrespective of arthritis development. In
addition to the lungs, mild inflammatory processes were observed in the hearts and
kidneys of some TS1xHACII mice, but were either not observed, or were only rarely
found in arthritic TS1(SW)xHACII mice (Fig. 3-5c). Evidence of intestinal inflammation
was not observed in either arthritic lineage.

Our visual assessment of TS1xHACII and TS1(SW)xHACII mice and their
subsequent designation as “arthritic” or “non-arthritic” was validated by the results
presented here. Of the male TS1(SW)xHACII mice that developed arthritis, their scores
for synovitits and articular degeneration were significantly lower than those from arthritic
female mice; this is noteworthy since we also observed a delayed onset of disease in
male TS1(SW)xHACII mice. Together, these data suggest that gender-associated
factors (such as sex hormones) may play a role in promoting the extent of arthritis
development and the degree of arthritis severity in the low affinity, TS1(SW)xHACII
mouse model of arthritis. Lastly, the lower affinity TCR in TS1(SW)xHACII mice is
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associated with a reduction of the extra-articular inflammation that occurs in TS1xHACII
mice.

+

3.2.5 Autoreactivity of CD4 T cells from TS1xHACII and TS1(SW)xHACII mice

Since inflammatory arthritis develops in mice co-expressing HA as a surrogate
self-antigen with a transgenic TCR that recognizes the self-HA, we first wanted to
assess the CD4+ T cells, and importantly the clonotypic CD4+ T cells, in TS1xHACII and
TS1(SW)xHACII mice. Despite having been subjected to extensive negative selection in
the thymus, a small population of clonotypic CD4+ T cells could be found in the spleens,
a systemically draining peripheral lymphoid organ, of pre-arthritic TS1xHACII and prearthritic TS1(SW)xHACII mice. Moreover, both 6.5+CD4+ and V8.3+CD4+ T cells
expressed an activated phenotype, more so than the remaining fraction of nonclonotypic CD4+ T cells in the same mouse and CD4+ T cells from control TCR single
transgenic mice, implicating the autoreactive nature of 6.5+CD4+ and V8.3+CD4+ T cells
(Fig. 3-6a-d). Notably though, the extent of 6.5+CD4+ T cell activation is considerably
higher than that of V8.3+CD4+ T cells. This appears to be another reflection of the
affinities of the TS1 and TS1(SW) TCR for the HA self-antigen.

To measure the degree of autoreactivity of CD4+ T cells in TS1xHACII and
TS1(SW)xHACII mice, we performed an in vitro autologous mixed lymphocyte reaction
(autologous MLR) assay. Total CD4+ T cells from arthritic TS1xHACII and arthritic
TS1(SW)xHACII mice were FACS sorted and CFSE-labeled. These T cells were then
plated with unfractionated splenocytes from various mice as sources of APCs.
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“Autologous splenocytes” were obtained from the spleens of TS1xHACII or
TS1(SW)xHACII mice and were plated with CD4+ T cells sorted from the same mouse;
HACII splenocytes were obtained from HACII mice where we know HA is expressed and
can stimulate T cell proliferation (Fig. 3-2c); BALB/c splenocytes were from BALB/c mice
(which, besides HA, should express the same self-antigens as HACII APCs); and
BALB/c splenocytes plus anti-CD3 acted as a positive control. In these experiments, T
cells and splenocytes were isolate from individual mice (i.e. cells from multiple mice
were not pooled) as to be able to obtain independent data from separate mice. Three
days after the co-culture was set up, we evaluated each stimulation condition for their
ability to induce T cell proliferation (as measured by CFSE dilution). Total CD4+ T cells
from both TS1xHACII and TS1(SW)xHACII mice did not proliferate in the presence of
BALB/c splenocytes but proliferated robustly to anti-CD3 stimulation (Fig. 3-7). In the
presence of autologous splenocytes, CD4+ T cells from TS1xHACII mice underwent
division in response to self-antigens being presented, but CD4+ T cells from
TS1(SW)xHACII mice underwent little to no proliferation. The lack of proliferation
observed with TS1(SW)xHACII T cells could be due to the reactivity of the T cells or
because HA presentation by autologous TS1(SW)xHACII splenocytes was reduced or
absent. However, co-culture of CD4+ T cells from TS1(SW)xHACII mice with HACII
splenocytes yielded the same results and we observed little to no dilution of CFSE in this
stimulation condition as well. On the other hand, TS1xHACII T cells underwent division
in the presence of HACII splenocytes, similar to what we observed with autologous
splenocytes.

These data show that pre-arthritic TS1xHACII and TS1(SW)xHACII mice contain
clonotypic CD4+ T cells that display an activated phenotype (Fig. 3-6). Together with
61

62

results from an autologous MLR, we demonstrate that the extent of autoreactivity of
clonotypic CD4+ T cells from TS1xHACII and TS1(SW)xHACII mice relative to each
other was maintained. In other words, 6.5+CD4+ T cells from TS1xHACII mice
maintained a higher level of reactivity to S1 peptide relative to V8.3+CD4+ T cells from
TS1(SW)xHACII mice. Therefore, despite subjection to multiple mechanisms of
tolerance induction, CD4+ T cells in TS1xHACII and TS1(SW)xHACII mice do not appear
completely tolerized.

3.2.6 Th1 and Th17 cells accumulate in arthritic TS1xHACII and TS1(SW)xHACII
mice

To assess whether changes in CD4+ T cell populations coincided with the
presence of disease, we compared the representation of total and clonotypic CD4+ T
cells in the LNs capable of draining the joints (pooled axillary, brachial and popliteal LNs;
joint-draining LNs; jdLN) and spleens of TS1xHACII and TS1(SW)xHACII mice before
and after arthritis development. With the exception of CD4+ T cells in the spleens and
V8.3+CD4+ T cells in the jdLN of TS1(SW)xHACII mice, total CD4+ and clonotypic CD4+
T cell populations were either not significantly different or lower in mice after disease
onset (Fig. 3-8a and b). Also, it did not appear that clonotypic CD4+ T cells specifically
accumulate in the jdLN compared to the spleens of arthritic mice. Rather than in T cell
populations, the most dramatic change linked to disease status is the significant
increase in jdLN cellularities of both arthritic TS1xHACII and TS1(SW)xHACII mice.
Spleen cellularities were also significantly increased in arthritic TS1(SW)xHACII mice
and modestly increased in arthritic TS1xHACII mice.
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Although the representation of total and clonotypic CD4+ T cells did not, for the
most part, increase after disease onset, we wanted to examine if the CD4+ T cells in
arthritic TS1xHACII and TS1(SW)xHACII mice gained an effector phenotype which
associates with the presence of inflammatory arthritis. Increased frequencies of Th1 and
Th17 cells, but not Th2 cells, are associated with inflammatory arthritis in mice and
humans (Miossec and van den Berg 1997, Mauri et al. 2003). Because of this, we
compared the representation of IFN-- and IL-17-producing CD4+ T cells in arthritic and
pre-arthritic double transgenic mice as well as in non-arthritic TCR single transgenic
mice. Within the total CD4+ and 6.5+CD4+ T cell populations (isolated from the jdLN and
re-stimulated ex-vivo), increased frequencies of both IFN-+ and IL-17+ cells were
observed in TS1xHACII mice relative to control TS1 mice (Fig. 3-9a and b). In line with
previous findings in this model system (Simons et al. 2013), we observed a dramatic
polarization of CD4+ and 6.5+CD4+ T cells to a Th1 phenotype in pre-arthritic TS1xHACII
mice. However, in mice with active disease, we found reduced frequencies of Th1 cells
compared to pre-arthritic mice and a concurrent increase in the frequency of IL17+6.5+CD4+ T cells.

Pre-arthritic TS1(SW)xHACII mice also contained significantly higher frequencies
of IFN-- and IL-17-producing CD4+ and V8.3+CD4+ T cells relative to control TS1(SW)
mice (Fig. 3-9c and d). Examination of CD4+ T cell populations isolated from arthritic
TS1(SW)xHACII mice revealed even higher frequencies IFN-+ and IL-17+ T cells, both
of which were significantly increased over that found in pre-arthritic mice. This is in
contrast to what occurred in TS1xHACII mice as the reduction of Th1 cells that occurred
after arthritis onset in the high affinity system was not observed in TS1(SW)xHACII mice.
65

66

Notably, CD4+ and V8.3+CD4+ T cells in TS1(SW)xHACII mice polarized toward a Th17
phenotype more so than to a Th1 phenotype (note the difference in scales in Fig. 3-9d).

Collectively, these data show that rather than increases in the general
representation of total or clonotypic CD4+ T cells, the appearance of disease in arthritic
TS1xHACII and TS1(SW)xHACII mice coincided with these T cell populations acquiring
the ability to produce IL-17. Of note, even before the onset of disease, TS1xHACII and
TS1(SW)xHACII mice contained significantly higher frequencies of Th1 and Th17 cells
compared to their age-matched TCR single transgenic counterparts. Thus, these data
implicate a pathogenic role for Th17 cells in the development of arthritis in both
TS1xHACII and TS1(SW)xHACII mice. Indeed, treatment with an anti-IL-17 mAb
abrogated arthritis development in TS1xHACII mice (Oh et al. 2012, Simons et al. 2013).

3.2.7 TCR affinity affects the extent of systemic immune activation in arthritic
mice

Because we found significantly higher frequencies of IFN-+ and IL-17+ CD4+ T
cells in arthritic TS1xHACII and TS1(SW)xHACII mice by intracellular cytokine staining,
we wanted to assess the actual levels of IFN- and IL-17 present in these mice. For this
purpose, we performed a Luminex assay with serum obtained from arthritic mice. In
addition to IFN- and IL-17, we chose to examine the levels of the pro-inflammatory
cytokines TNF-a, IL-6 and IL-1B (and the anti-inflammatory cytokine IL-10) as they all
were found to be upregulated in the serum and synovial fluid of RA patients (Steiner et
al. 1999, Feldmann 2002, McInnes and Schett 2011, Metawi et al. 2011); as described in
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Chapter 1, their contributions to disease pathogenesis have also been explored in detail.
The Luminex results revealed that the serum of TS1xHACII mice, in comparison to TCR
single transgenic controls, contained significantly elevated levels of all of the cytokines
examined (Fig. 3-10a). On the other hand, only IL-6 was moderately elevated and IL-17
was significantly elevated in the serum of TS1(SW)xHACII mice relative to controls;
levels of IL-17 were not significantly different in TS1(SW)xHACII mice compared to
TS1xHACII mice. Arthritic TS1xHACII mice also contained significantly higher levels of
serum IgG than control mice expressing only the TCR transgene, and while serum IgG
was also elevated in arthritic TS1(SW)xHACII mice relative to controls, it was
significantly lower than in TS1xHACII mice (Fig. 3-10b).

Collectively, these data demonstrate that that the extent of systemic immune
activation can be affected by the affinity with which autoreactive CD4+ T cells recognize
a target self-antigen. Interestingly, these results suggest that elevated levels of multiple
pro-inflammatory cytokines are not necessary for the development of arthritis, as
TS1(SW)xHACII mice which contain overall low levels of cytokines can develop disease;
rather, the contribution of IL-6 and/or IL-17 may be important.

3.2.8 Inflammatory arthritis develops by an IL-17-dependent mechanism in
TS1(SW)xHACII mice

Due to the previous findings showing that arthritic TS1(SW)xHACII mice
contained high frequencies of IL-17+ CD4+ T cells and elevated levels of IL-17 in the
serum (Fig. 3-9 and Fig. 3-10), we wanted to ascertain whether IL-17 is necessary for
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disease development in TS1(SW)xHACII mice. IL-17 has been shown to play an
important and pathogenic role in multiple mouse models of arthritis (including the
TS1xHACII mouse model) (Hirota et al. 2007, Wu et al. 2010, Oh et al. 2012), and
importantly, a role for IL-17 has also been implicated in RA (Ziolkowska et al. 2000,
Metawi et al. 2011). For this purpose, we treated pre-arthritic TS1(SW)xHACII mice with
an anti-IL-17R mAb, which has been reported to block the interaction of IL-17 with its
receptor (Maitra et al. 2007), or with an isotype control mAb and monitored for disease
development (Fig. 3-11a). Strikingly, we found that treatment with anti-IL-17R
completely abrogates arthritis development in TS1(SW)xHACII mice. Of note, serum
from anti-IL-17R treated mice contained significantly higher concentrations of IL-17
compared to both TS1(SW) and isotype control-treated TS1(SW)xHACII mice, indicating
that the consumption of IL-17 was blocked with anti-IL-17R treatment (Fig. 3-11b).

Together, these results show that anti-IL-17R treatment significantly attenuates
disease development in TS1(SW)xHACII mice. Therefore, inflammatory arthritis can
develop by an IL-17-dependent mechanism in the low affinity mouse model
(TS1(SW)xHACII mice) as well.
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3.3 Discussion

Genetic associations to MHCII alleles in human patients and findings extracted
from mouse models strongly implicate the central role of autoreactive CD4+ T cells in the
pathogenesis of inflammatory arthritis. The data we present in this chapter demonstrate
that altering the affinity of CD4+ T cells to a single target autoantigen can have profound
effects on disease course and the extent of systemic immune activation.

We began this project to examine how CD4+ T cell recognition of self-antigen(s)
can influence the development of autoimmunity. Using a model system of inflammatory
arthritis where the specificities of the disease eliciting CD4+ T cells and target
autoantigen are both known (TS1xHACII mice) ((Rankin et al. 2008) and Fig. 3-1)), we
explored the outcome of altering the CD4+ T cell response to that single target antigen.
Therefore, TS1(SW)xHACII mice were generated, in which the mouse expressing the
target antigen from TS1xHACII mice was crossed with a mouse expressing a transgenic
TCR with low (rather than high) affinity for that antigen (Fig. 3-3a). Notably, to generate
TS1(SW)xHACII mice, we used an entirely different TCR transgene than was used to
generate TS1xHACII mice and there are appreciable differences in these two TCRs.
Besides using different / chain combinations (see Materials and Methods), the
TS1(SW) TCR is a much better allelic excluder than the TS1 TCR (Fig. 3-2d).
Therefore, how can we claim to have influenced disease outcome by altering the CD4+ T
cell response to just PR8 HA? What if we think about it this way: there is no evidence of
inflammatory arthritis development in TCR single transgenic mice, so it is the
introduction of PR8 HA as a neo-self antigen that prompts disease onset in both
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TS1xHACII and TS1(SW)xHACII mice. In other words, co-expression of the TCR
transgene with the HA transgene is necessary to drive inflammatory arthritis in both
model systems. We cannot exclude, however, the possibility that autoreactive CD4+ T
cell specificities exist in double transgenic mice that were not present in single
transgenic mice. Autoreactive / TCR combinations may emerge from stochastic
rearrangements of endogenous TCR chains in order to compensate for the extensive
thymic deletion of clonotypic T cells in each double transgenic system ((Rankin et al.
2008) and Fig. 3-2d)). It is also possible that the initial interactions of the autoreactive
TCR with self-antigen leads to the bystander activation of other T cell specificities
(determinant / epitope spreading) (Lehmann et al. 1992). Indeed, we can find nonclonotypic CD4+ T cells capable of producing IFN- and IL-17 in TS1xHACII and
TS1(SW)xHACII mice (Fig. 3-9). Nonetheless, the autoimmune reaction that unfolds in
double transgenic (but not TCR single transgenic) mice argues that, in each case, the
CD4+ T cell response specifically to the neo-HA antigen drives the development of
autoimmune arthritis.

As previously reported and repeated here, TS1xHACII mice develop a highly
penetrant and severe form of inflammatory arthritis that is accompanied by extraarticular inflammatory manifestations ((Rankin et al. 2008) and Fig. 3-1, 4, 5)). The
introduction of a low affinity TCR for the autoantigen still resulted in the development of
arthritis in TS1(SW)xHACII mice, but compared to the high affinity model system
(TS1xHACII mice), the overall penetrance of disease in TS1(SW)xHACII mice was
significantly lower (due to fewer males developing arthritis) and we could find little to no
evidence of inflammation in extra-articular tissues (Fig. 3-3, 4, 5). These findings were
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interesting because there could have been several possible outcomes following the
introduction of the low affinity TCR. Indeed, SKG mice with varying numbers of wildtype, mutant and null ZAP-70 alleles (and therefore graded extents of TCR signaling)
displayed altered disease spectrums (Tanaka et al. 2010). Therefore, we might have
discovered that TS1(SW)xHACII mice do not develop autoimmunity; they could have
developed a different type of autoimmune disease in lieu of arthritis; or they could have
developed arthritis that replicates the disease observed in TS1xHACII mice. Strikingly,
these findings demonstrate that the autoreactive CD4+ T cell responses that occurs in
both TS1xHACII and TS1(SW)xHACII mice promote a joint-targeted disease.

Nonetheless, tolerance is broken in both TS1xHACII and TS1(SW)xHACII mice,
resulting in autoimmune arthritis. This occurs despite the subjection of CD4+ T cells in
both systems to multiple mechanisms of tolerance induction. Clonotypic CD4+ T cells
were negatively selected in the thymii of TS1xHACII and TS1(SW)xHACII mice in which
the fold-reduction observed in each case correlated to the affinity of the T cells for the S1
autoantigen (Fig. 3-2). We also found that clonotypic CD4+ T cells that develop in the
presence of S1 as a self-antigen expressed appreciably lower levels of TCRs on their
surface compared to their TCR only counterparts, as demonstrated by flow cytometry
((Rankin et al. 2008) and Fig. 3-2d)). Furthermore, possibly due to the reduced density
of TCRs on their surface, S1-specific CD4+ T cells from TS1xHACII and TS1(SW)xHACII
mice displayed a heavily modulated reactivity to the S1 self-peptide compared to T cells
isolated from TS1 and TS1(SW) mice, respectively (compare number of peaks in Fig. 32c to Fig. 3-7). These attempts at tolerance induction, however, failed and CD4+ T cells
with an activated, effector phenotype can be found in the periphery of TS1xHACII and
TS1(SW)xHACII mice.
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It was interesting to find that, despite having a low affinity for the S1 self-antigen,
the expression of the TS1(SW) TCR was sufficient to break tolerance and drive disease
development in TS1(SW)xHACII mice. It is still unclear to what degree autoreactive
CD4+ T cells need to be stimulated in order for this to happen (Siggs et al. 2007, Tanaka
et al. 2010). This concept is interesting to consider because not all mice containing a
transgenic TCR specific for self-antigen develop autoimmunity. An example of this from
our lab is the TS1xHA104 mouse. HA104 mice were also generated with a PR8 HA
transgene but its expression is driven by a SV40 early region promoter/enhancer (Caton
et al. 1996, Riley et al. 2000); relative to HACII mice, HA104 mice express low levels of
HA that is systemically distributed and the synthesis of HA is not limited to APCs. Of
note, APCs in HA104 mice can present S1 peptide to TS1 T cells but are considerably
less stimulatory than HACII APCs (Rankin et al. 2008). Similar to TS1xHACII mice,
6.5+CD4+ T cells in TS1xHA104 mice were subjected to negative selection in the thymus
(the extent of their deletion was extensive but less so than in TS1xHACII mice), but can
again be found in the periphery (Rankin et al. 2008). However, in striking contrast to
TS1xHACII mice, TS1xHA104 mice do not develop inflammatory arthritis. One reason
for why this disparate outcome in disease development may occur could be due to the
amount of antigen presented in each system. This suggests that CD4+ T cells need to
surpass a certain TCR stimulation threshold in order to break self-tolerance; simply the
development of self-specific T cells in the presence of their cognate antigen does not
guarantee that they will break self-tolerance. Therefore, taking the results of the
TS1xHA104 mice into consideration, it would imply that CD4+ T cells in the
TS1(SW)xHACII model system, despite expressing a low affinity TCR for the target selfantigen, were sufficiently stimulated to acquire effector functions and promote
autoimmunity due to the high amounts of self-antigen that is constitutively presented by
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APCs. This suggests that further reducing clonotypic TCR stimulation in
TS1(SW)xHACII mice (for example, by crossing them onto a TCR signaling mutant) or
removing a source of antigen (for example by crossing them onto a B cell- or DCdeficient background – see next chapter) may abrogate disease development in these
mice so that they resemble TS1xHA104 mice.

Along these lines, the ability of CD4+ T cell affinity to influence the development
of autoimmune arthritis does not appear to be binary – that arthritis can develop with an
“intermediate” phenotype as can be observed in the incomplete penetrance of disease in
TS1(SW)xHACII mice, especially in males (Fig. 3-3d). Interestingly, the extent of
disease development (penetrance and severity) coincided with the extent of systemic
immune activation. Not unlike how high affinity ligands can elicit a strong T helper
response in other settings (Ahlers et al. 2001, Diepolder et al. 2001), CD4+ T cells
bearing a high affinity TCR for the S1 self-antigen in TS1xHACII mice were associated
with complementary APC activation (Rankin et al. 2008) and elevated systemic levels of
IgG and multiple inflammatory cytokines ((Rankin et al. 2008) and Fig. 3-10)). In line
with this, the degree of systemic immune activation in the low affinity model,
TS1(SW)xHACII mice, was clearly less pronounced.

In conclusion, we have demonstrated that the affinity with which a CD4+ T cell
recognizes a target self-antigen can prominently affect the development of inflammatory
arthritis. Although extensive studies in humans and in mouse models support the
conclusion that CD4+ T cells can promote arthritis development, how CD4+ T cells
recognize self-antigen is unknown. This is especially hard to study in humans since the
disease eliciting antigen(s) are not well defined. Furthermore, this issue has largely not
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been addressed in other mouse models of arthritis. Therefore, we believe our work
provides unique insights on how the affinity of a CD4+ T cell response can direct the
development of inflammatory arthritis.
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Chapter 4: CD4 T cell reactivity can influence the pathways by which
inflammatory arthritis develops

4.1 Introduction

As described in detail in Chapter 1, the factors and cellular populations shown
capable of participating in the development of inflammatory arthritis are numerous.
Furthermore, not only can these factors work in concert to drive disease, but it can be
argued that each factor could play multiple, possibly mutually exclusive, roles. For
example, B cells can secrete inflammatory cytokines, serve as APCs and/or produce
arthritogenic antibodies. TNF is capable of reinforcing an inflammatory cytokine
cascade, inhibit Tregs and/or induce the expression of chemokines directly in the joints.
In light of this, maybe it is not surprising that lineages of mice engineered to overexpress inflammatory cytokines (like TNF or IL-1), found to contain mutated TCR
signaling molecules (like SKG mice), or developed to co-express a transgenic TCR and
a known target autoantigen (like K/BxN and TS1xHACII mice) all develop manifestations
of inflammatory arthritis. These findings highlight the complexity of an autoimmune
disorder which begins with a breach in self-tolerance and ultimately results in a jointtargeted disease. Furthermore, these findings suggest that the potential therapeutic
targets for the treatment of arthritis are extensive.

Indeed, several reagents directed at distinct targets exist for the treatment of
inflammatory arthritis. Anti-TNF reagents, which were the first biologic therapies
developed for RA, have high response rates, but nonetheless, are not effective in all RA
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patients (Lipsky et al. 2000, Feldmann 2002). This has led to the evaluation of
antagonists targeting other pro-inflammatory cytokines (including IL-1, IL-6 and IL-17) for
their therapeutic efficacy (Cohen et al. 2002, Nishimoto et al. 2004, Genovese et al.
2010). Additionally, anti-B cell reagents, such as rituximab, have proven effective in
many RA patients and are usually the next line of treatment after anti-TNF fails (Edwards
et al. 2004, Higashida et al. 2005, Cohen et al. 2006). These findings again highlight the
complexity as well as the heterogeneity of the diseases classified as inflammatory
arthritis, as there is not currently one course of treatment that is effective in all patients.
Therefore, a major hurdle for physicians in determining the appropriate treatment for
arthritis patients is that they cannot predict what therapeutic reagent each patient would
be responsive to; predictors of response to particular therapies have yet to be elucidated
(Isaacs 2010). Progress on this issue has been limited because it is unclear what could
dictate the predominant pathway(s) of pathogenesis (cytokines vs B cells) in each
individual patient. A simple explanation could be that distinct autoantigens are targeted
by the immune system in patients that respond to different therapeutic strategies.
However, an alternative explanation is that qualitative and/or quantitative differences in
the autoreactive CD4+ T cell response that drives the disease process can determine
which cellular pathways take prominence. These hypotheses are difficult to assess in
human patients because the self-antigens that are recognized remain poorly
characterized (Bennett et al. 2003, Trouw and Mahler 2012).

As demonstrated in the previous chapter, inflammatory arthritis was found to
arise in both TS1xHACII and TS1(SW)xHACII mice, despite having been generated with
transgenic TCRs that have different affinities for the same S1 autoantigen. However, the
development of disease, with regard to disease penetrance and the extent of systemic
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immune activation, significantly differed between these two mouse models. In this
chapter, we wanted to also assess the pathways by which disease develops in
TS1xHACII and TS1(SW)xHACII mice. In the following experiments, we show that in the
context of a highly reactive CD4+ T cell response to a single self-peptide in TS1xHACII
mice, B cells are not required for arthritis development, although pro-inflammatory
cytokines such as TNF are required. Conversely, eliminating B cells significantly
suppresses disease development in the context of a weakly autoreactive CD4+ T cell
response in TS1(SW)xHACII mice, and TNF in this system appears to play a less
prominent role than B cells (as well as a less prominent role than in the TS1xHACII
model system). Additional pathways appear to also be required to support arthritis
development in TS1(SW)xHACII mice because disease develops with a pronounced
female bias in this setting (Fig. 3-3d). Collectively, these studies reveal that
fundamentally different pathways of pathogenesis exist in TS1xHACII and
TS1(SW)xHACII mice. Thus, we believe we have demonstrated that the degree of CD4+
T cell reactivity for self-peptide(s) can play a prominent role in determining the cellular
pathways that participate in the development of inflammatory arthritis.
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4.2 Results

4.2.1 B cell elimination significantly attenuates disease development in
TS1(SW)xHACII mice but not in TS1xHACII mice

To begin to assess whether differences in the degree of the autoreactive CD4+ T
cell response could influence the pathways by which inflammatory arthritis develops, we
first examined if B cells play a prominent role in TS1xHACII and TS1(SW)xHACII mice.
As previously shown, serum IgG titers, used as a measure of B cell activity, were
significantly higher in arthritic TS1xHACII mice compared to control mice expressing only
the TCR transgene (Fig. 3-10b). Furthermore, B cells in the spleens of TS1xHACII mice
were previously reported to express elevated levels of CD86 and MHCII (Rankin et al.
2008). All of these data indicate that highly activated B cells populate TS1xHACII mice.
Serum IgG was also elevated in arthritic TS1(SW)xHACII mice relative to controls, but it
was significantly lower than in TS1xHACII mice (Fig. 3-10b).

To definitively determine if B cells and/or their products are required for arthritis
development, we mated TS1xHACII and TS1(SW)xHACII mice onto a JH-/-background
(Chen et al. 2003) in order to generate mice that congenically lacked B cells. Cohorts of
TS1xHACII.JH-/- mice, TS1(SW)xHACII.JH-/- mice, as well as B cell sufficient TS1xHACII
and TS1(SW)xHACII mice, were then assessed weekly for arthritis development. As
previously reported (Rankin et al. 2008) and expanded on here, the penetrance and
severity of disease in TS1xHACII.JH-/- mice did not differ compared to TS1xHACII mice,
indicating that B cells are not required for arthritis development in this system (Fig. 4-1a).
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Notably, we observed a marked acceleration of disease onset in TS1xHACII.JH-/- mice,
suggesting that there may be a protective role for B cells in TS1xHACII mice. In striking
contrast, when disease development was assessed in the low affinity system, we found
significantly fewer TS1(SW)xHACII.JH-/- mice to have developed disease compared to
their B cell sufficient counterparts (3/17 vs 14/16, respectively, at 14 weeks of age); and
of the TS1(SW)xHACII.JH-/- mice that did develop disease, their severity scores were
generally low (Fig. 4-1b).

Despite the presence of highly elevated serum IgG titers and systemically
activated B cells in TS1xHACII mice, B cells are not a required immune cell population
for the development of arthritis in this model system (Fig. 3-10b, Fig. 4-1 and ref). In
striking contrast, B cells make a significant contribution to arthritis development in
TS1(SW)xHACII mice - a setting where CD4+ T cells recognize self-antigen with low
reactivity. Therefore, interestingly, B cells significantly contribute to disease
development in a setting where serum cytokines levels are low and the opposite is true
in a setting with high levels of serum cytokines.

4.2.2 TS1(SW)xHACII mice do not contain elevated levels of arthritogenic
autoantibody specificities

Since B cells make an important contribution to arthritis development in
TS1(SW)xHACII but not TS1xHACII mice, we next examined if autoantibody specificities
associated with inflammatory arthritis (Hueber et al. 2005, Isenberg et al. 2007) were
present/elevated in arthritic TS1(SW)xHACII mice. To this end, we performed ELISAs to
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measure the concentrations of autoantibodies in the serum of arthritic TS1(SW)xHACII
mice in comparison to arthritic TS1xHACII and control TCR single transgenic mice.
However, we found no differences in the levels of rheumatoid factor (RF), antibodies to
type II collagen, or antibodies to double-stranded DNA (anti-dsDNA) in arthritic
TS1(SW)xHACII mice compared to control TCR only mice or to arthritic TS1xHACII mice
(Fig. 4-2a). Sera from TS1xHACII mice actually had higher levels of anti-cyclic
citrullinated peptide (anti-CCP) antibodies relative to TS1(SW)xHACII mice. Although
the presence of anti-CCP antibodies is currently the best diagnostic marker for RA, the
citrullination of proteins can occur in other inflammatory settings (Vossenaar et al. 2004).
Therefore, increased anti-CCP levels in TS1xHACII mice may simply reflect the high
level of systemic inflammation present in the mouse (Fig. 3-10a).

To further assess if autoreactive antibodies contribute to disease development in
TS1(SW)xHACII mice, we attempted to elicit disease by performing serum transfers.
Serum (specifically the antibodies in the serum) from K/BxN mice has been shown to
induce rapid and robust arthritis development following transfer into naïve BALB/c mice
(Korganow et al. 1999). Utilizing the same protocol, we transferred serum from arthritic
TS1(SW)xHACII mice into various hosts and monitored for the appearance of arthritis.
We also transferred K/BxN serum into separate mice as positive controls. As expected,
arthritis was induced in all recipients of K/BxN serum (Fig. 4-2b). We did not, however,
observe any indication of inflammation or swelling in the paws of TS1(SW)xHACII serum
recipients.
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Collectively, these results suggest that the ability of B cells to promote arthritis
development in TS1(SW)xHACII mice does not appear to be through a mechanism
driven by arthritogenic autoantibodies.

4.2.3 B cells support clonotypic Th17 cells for the development of arthritis in
TS1(SW)xHACII mice

As B cells do not seem to act as a source of pathogenic autoantibodies in
TS1(SW)xHACII mice, we evaluated whether B cells provide support for effector CD4+ T
cells as APCs in this system. To perform this analysis, we compared CD4+ T cell
subsets from arthritic TS1(SW)xHACII, arthritic TS1(SW)xHACII.JH-/- and non-arthritic
TS1(SW)xHACII.JH-/- mice that were described in Fig. 4-1b. Consistent with the
absence of B cells, TS1(SW)xHACII.JH-/- mice had significantly smaller joint-draining
LNs (jdLNs) and spleens than TS1(SW)xHACII mice; jdLN and splenic cellularities did
not differ between TS1(SW)xHACII.JH-/- mice that did and did not develop arthritis (Fig.
4-3a). By the same token, we found significantly higher frequencies of CD4+ T cells in
both sets of TS1(SW)xHACII.JH-/- mice due to the absence of B cells. Lower
frequencies of V8.3+V10+ CD4+ T cells were found in non-arthritic TS1(SW)xHACII.JH/-

mice relative to both sets of arthritic mice, however, this difference was not statistically

significant. Of note, arthritic TS1(SW)xHACII.JH-/- mice contained similar frequencies of
V8.3+V10+ CD4+ T cells as arthritic TS1(SW)xHACII mice, indicating that B cells are
not necessary to maintain the clonotypic CD4+ T cell population in this model system.
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Importantly, we wanted to evaluate whether the representation of cytokineproducing effector CD4+ T cells were altered in TS1(SW)xHACII.JH-/- mice. Within the
total CD4+ T cell population, high frequencies of IFN-+ and IL-17+ cells were found in
both the jdLNs and spleens of all sets of mice examined, irrespective of the presence or
absence of B cells or disease (Fig. 4-3b and c). Within the clonotypic CD4+ T cell
population, however, we observed significantly lower frequencies of IFN-+ cells in both
arthritic and non-arthritic TS1(SW)xHACII.JH-/- mice compared to B cell sufficient
TS1(SW)xHACII mice. In other words, B cells appeared to support clonotypic IFN-producing CD4+ T cells; reduced frequencies of these cells, however, did not correlate
with disease status. On the other hand, reduced frequencies of clonotypic Th17 cells
was observed in non-arthritic TS1(SW)xHACII.JH-/- mice but no such reduction of these
cells was found in arthritic mice.

Foxp3+ regulatory T cells (CD4+CD25+Foxp3+, Tregs) are regarded as an
essential immune subset required for maintaining peripheral self-tolerance (Sakaguchi et
al. 2008, Shevach 2009). Therefore, a large focus in the field of Treg biology has been
to examine not only how Tregs are generated but also how they are maintained. Of
concern to us, several studies have reported that B cells can act to expand and induce
Tregs (Chen and Jensen 2007, Morlacchi et al. 2011, Ray et al. 2012). These results,
however, seem contradictory to our finding that disease is ameliorated in B cell deficient
TS1(SW)xHACII.JH-/- mice. Because of this, we examined if the representation of Tregs
in TS1(SW)xHACII mice was affected by the elimination of B cells. Firstly, we found that
B cell sufficient TS1(SW)xHACII mice contained significantly higher frequencies of Tregs
compared to control TS1(SW) mice in both the jdLNs and spleens (Fig. 4-4a and b).
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Secondly, we found that the frequency of Tregs in TS1(SW)xHACII.JH-/- mice did not
significantly differ from TS1(SW)xHACII mice. Thirdly, arthritic and non-arthritic
TS1(SW)xHACII.JH-/- mice were found to contain similar frequencies of Tregs.

Interestingly, arthritis persists in TS1(SW)xHACII mice in the presence of
elevated frequencies of Tregs. It is possible, though, that Tregs in arthritic
TS1(SW)xHACII mice are dysfunctional. To assess the suppressive capability of Tregs
from arthritic TS1(SW)xHACII mice, we performed a classic in vitro Treg suppression
assay. CD4+CD25- responder T cells from TS1(SW) mice were CFSE-labeled and cocultured with CD4+CD25+ Tregs isolated from either BALB/c or arthritic TS1(SW)xHACII
mice in the presence of anti-CD3 stimulation. Responder T cells proliferated robustly in
response to anti-CD3 in the absence of Tregs (Fig. 4-4c). The addition of BALB/c Tregs
considerably suppressed the proliferation of responder cells. Notably, in this assay,
TS1(SW)xHACII Tregs were just as suppressive (and may even be more suppressive)
than BALB/c Tregs.

Collectively, these data show that B cells are not required to maintain Tregs in
TS1(SW)xHACII mice and an increase in Tregs does not account for the absence of
arthritis in the majority of TS1(SW)xHACII.JH-/- mice. On the other hand, B cells were
shown to support the differentiation and/or accumulation of IFN-- and IL-17-secreting
effector CD4+ cells expressing the clonotypic V8.3+V10+ TCR. However, only the
reduction of IL-17+V8.3+V10+ CD4+ T cells significantly correlated with the absence of
disease in TS1(SW)xHACII.JH-/- mice. Thus, since the preceding results showed that
anti-IL17R blockade can also prevent arthritis, these studies suggest that B cells
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promote disease in TS1(SW)xHACII mice at least in part by supporting the formation of
pathogenic Th17 cells expressing the autoreactive V8.3+V10+ TCR.

4.2.4 Anti-B cell treatment prevents arthritis development in TS1(SW)xHACII mice

It was possible that the reduced Th1 and Th17 cell frequencies observed in
TS1(SW)xHACII.JH-/- mice were a consequence of an improperly developed immune
system that arose due to the congenital lack of B cells. We therefore examined the
effects of eliminating B cells from mice in which B cell development had been allowed to
occur. To this end, we treated 5 week old TS1(SW)xHACII mice with anti-CD20 (Hamel
et al. 2008) (Fig. 4-5a). Anti-CD20 mAbs target and deplete CD20-expressing B cells,
namely immature pre-B cells and all mature B cells except plasma cells (Edwards and
Cambridge 2006); of note, anti-CD20 treatment was also found capable of depleting
short-lived plasmablasts with autoreactive specificities (Huang et al. 2010). Therefore,
we first assessed the efficacy of the reagent in depleting B cells and its effect on serum
antibody titers. Indeed, 10 out of 13 TS1(SW)xHACII mice that received anti-CD20
treatment contained little to no CD19+ B cells in the spleens (Fig. 4-5b) and significantly
lower concentrations of IgG in the serum (Fig. 4-5c) compared to isotype control-treated
mice. Three of the anti-CD20 treated mice were, however, refractive to complete B cell
depletion; although the frequencies of splenic CD19+ B cells were significantly reduced
in these mice compared to isotype control-treated mice, they were still significantly
higher than in the remaining anti-CD20 treated mice (Fig. 4-5b) and so these individuals
were designated as “semi-depleted”.
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Weekly assessment of disease development in these treated cohorts revealed
results similar to what we observed in TS1(SW)xHACII.JH-/- mice in that the majority of
anti-CD20 treated TS1(SW)xHACII mice (10/13) did not develop arthritis (Fig. 4-5d).
Interestingly, the number of mice that did develop arthritis after anti-CD20 treatment is
the same as the number of mice in which B cell depletion was incomplete (3/13 in both
cases). Surprisingly, the anti-CD20 treated mice that developed arthritis were not the
“semi-depleted” mice. Indeed, none of the “semi-depleted” mice developed arthritis.
The three anti-CD20 treated TS1(SW)xHACII mice that developed disease came from
the group of mice in which CD19+ B cells and serum IgG had been significantly reduced.

Thus, these results again demonstrate that B cells are an important immune cell
population that promotes the development of arthritis in TS1(SW)xHACII mice. Notably,
these results support the conclusion that B cells are not required to act as a source of
arthritogenic antibodies in this system as: 1) arthritis can develop in TS1(SW)xHACII
mice lacking serum IgG and 2) TS1(SW)xHACII mice containing serum IgG do not
always develop disease.

+

4.2.5 Reduced frequencies of clonotypic cytokine-producing CD4 T cells
correlated with the absence of disease in anti-CD20 treated TS1(SW)xHACII mice

To assess changes in immune cell populations after anti-CD20 treatment, we
performed the same analysis as was previously done in TS1(SW)xHACII.JH-/- mice.
Since the number of “semi-depleted” non-arthritic mice and of anti-CD20 treated arthritic
mice were small (n=3 each) and the SEM of data sets from these mice were large, we
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only compared data from isotype control-treated TS1(SW)xHACII mice that developed
arthritis (n=12) and from anti-CD20 treated TS1(SW)xHACII mice that did not develop
arthritis (n=7) (Fig. 4-6a). Similar to the findings in TS1(SW)xHACII.JH-/- mice, the
depletion of B cells in TS1(SW)xHACII mice through anti-CD20 treatment led to
significantly reduced jdLN and spleen cellularities and increased percentages of CD4+ T
cells; the frequency of CD4+ T cells expressing the clonotypic TCR did not differ.

Additionally, we again observed significantly lower frequencies of IFN-+ and IL17+ cells within the clonotypic CD4+ T cell population in both the jdLN and spleens of
anti-CD20 treated mice (Fig. 4-6b and c), closely resembling the results from the
analysis of congenically B cell deficient TS1(SW)xHACII mice. However, we found
significantly lower frequencies of IL-17+ and IFN-+ cells within the total CD4+ T cell
population the jdLNs and spleens, respectively, of anti-CD20 treated mice, which
differed from what was observed in TS1(SW)xHACII mice where B cells were
congenically ablated. However, the fold reduction of cytokine-producing cells within the
total CD4+ T cell population was smaller than what occurred in the clonotypic CD4+ T cell
population. Moreover, the representation of Tregs in the jdLNs and spleens of antiCD20 treated mice were not largely different from that in isotype control-treated mice
(Fig. 4-6d).

Collectively, these findings provide additional evidence that B cells support the
development or accumulation of cytokine-secreting effector CD4+ T cells, especially
those expressing the autoreactive clonotypic TCR, in TS1(SW)xHACII mice.
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4.2.6 TNF neutralization ameliorates arthritis in TS1xHACII mice

Before B cell depletion was utilized as a therapy to treat RA, treatment with antiTNF was considered the gold standard due to the high patient response rates
(Feldmann 2002). Because TNF is elevated in the serum of arthritic TS1xHACII mice
and because B cells were found to not be essential in this system, we explored whether
targeting the TNF cytokine pathway could affect disease development in this model.
Treatment of pre-arthritic TS1xHACII mice with an anti-TNF antibody resulted in a
significant reduction in arthritis penetrance; of those individuals that did develop arthritis
despite receiving anti-TNF treatment, most exhibited lower arthritis scores than the
majority of isotype control-treated mice (Fig. 4-7a and b).

TNF has been shown capable of participating in an inflammatory cytokine
cascade which begets further elaboration of inflammatory cytokines and ultimately, joint
destruction (Feldmann 2002). It is thought that because of this, the reduced levels of
inflammatory cytokines, such as IL-1, IL-6 and IL-8, detected in anti-TNF treated patients
(Feldmann 2002) were a direct result of removing TNF signaling. Therefore, we wanted
to assess whether the neutralization of TNF in TS1xHACII mice affected serum cytokine
levels, particularly in mice that did not develop disease. However, we did not find a
global reduction of inflammatory cytokines in the blood of anti-TNF treated mice relative
to isotype control-treated mice (Fig. 4-7c). Anti-TNF treated mice that did not develop
arthritis contained lower levels of IL-6 relative to arthritic isotype control-treated mice, but
not less than in anti-TNF treated mice that developed arthritis.
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These data show that disease can be significantly attenuated in TS1xHACII mice
following treatment with a neutralizing mAb directed against TNF. Thus, although B cells
are not necessary for arthritis development in this system, the pathogenic involvement of
the inflammatory cytokines TNF and IL-17 (Oh et al. 2012) is evident. The prevention of
disease in TS1xHACII mice treated with anti-TNF, however, did not correlate with the
reduction of inflammatory cytokines that have been associated with arthritis.

4.2.7 Anti-TNF treatment did not augment Tregs in TS1xHACII mice

Studies in human RA patients have shown that a successful response to antiTNF treatment can be associated with increased frequencies and/or activity of Foxp3+
Tregs (Ehrenstein et al. 2004, Valencia et al. 2006, Nie et al. 2013). We therefore
examined the frequency of Tregs in anti-TNF treated TS1xHACII mice that did not
develop arthritis versus arthritic TS1xHACII mice that previously received either isotype
control or anti-TNF antibodies. As previously reported (Oh et al. 2012) and repeated
here, the frequencies of CD25+Foxp3+ CD4+ T cells were higher in both the jdLNs and
spleens of arthritic TS1xHACII mice than in control TS1 mice (Fig. 4-8a and b).
However, no significant differences were found in Treg frequencies between TS1xHACII
mice that had received the anti-TNF antibody and TS1xHACII mice that had received the
isotype control antibody. Thus, anti-TNF treatment did not augment Treg frequencies in
TS1xHACII mice, even in mice that were protected from arthritis development.

We also performed an in vitro Treg suppression assay to evaluate the
suppressive activity of Tregs isolated from anti-TNF treated TS1xHACII mice. Tregs
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sorted from the spleens of control BALB/c, arthritic isotype control-treated TS1xHACII
and non-arthritic anti-TNF treated TS1xHACII mice were co-cultured with CTV-labeled
CD4+CD25- responder cells obtained from arthritic isotype-control treated TS1xHACII
mice at various ratios. Compared to BALB/c Tregs (which were used as a positive
control), Tregs from both sets of TS1xHACII mice were neither worse nor better at
suppressing the proliferation of responder cells in vitro (Fig. 4-8c). Notably, Tregs
purified from non-arthritic anti-TNF treated TS1xHACII mice were no better at
suppressing the proliferation of responder cells than those from arthritic isotype controltreated TS1xHACII mice.

Collectively, these data argue against the possibility that anti-TNF treatment
modulates arthritis development in TS1xHACII mice through an ability to increase the
representation or activity of CD25+Foxp3+ Tregs.

4.2.8 Anti-TNF treatment prevented the accumulation of Th17 cells in the joints,
but not in the jdLNs or spleens, of TS1xHACII mice

We next examined if anti-TNF treatment modulates arthritis by affecting the
differentiation and/or accumulation of effector CD4+ T cells in the jdLN and spleens of
TS1xHACII mice. We again segregated data obtained from arthritic and non-arthritic
TS1xHACII mice that had all previously received the same anti-TNF treatment regimen.
The overall cellularity of the jdLNs (but not of the spleens) was reduced in anti-TNF
treated TS1xHACII mice that did not develop arthritis (Fig. 4-9a). Although there were
no significant differences in the frequencies of total CD4+ T cells between the sets of
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mice examined, a small but statistically significant reduction in the representation of
6.5+CD4+ T cells was observed in non-arthritic anti-TNF treated mice compared to
arthritic isotype control-treated mice. Furthermore, we actually found no significant
differences in the representations of Th1 and Th17 cells in both the total and clonotypic
CD4+ T cell populations of either sets of anti-TNF treated mice relative to each other or
to isotype control-treated mice (Fig. 4-9b and c).

As we could not find robust differences in the CD4+ T cell subsets isolated from
the jdLNs and spleens of anti-TNF treated TS1xHACII mice that did not develop arthritis,
we wanted to examine the immune cell populations within the actual site of inflammation,
namely, the joints. The same sets of treated mice as described in Fig. 4-8 and Fig. 4-9
were examined. As might be expected, we found that the overall number of cells
isolated from non-arthritic joints were fewer than that from inflamed joints (Fig. 4-10b).
One of the largest populations of immune cells found within arthritic joints, CD11b+
neutrophils, was found to be significantly reduced in anti-TNF treated mice that did not
develop arthritis (Fig. 4-10a and b). The frequencies of CD19+ B cells and CD4+ T cells
were, however, unaffected in anti-TNF treated TS1xHACII mice that did not develop
disease relative to both sets of arthritic mice. Notably, the frequency of IL-17-secreting
(but not of IFN--secreting) CD4+ T cells was significantly reduced in the joints of nonarthritic anti-TNF treated TS1xHACII mice. No such decrease in the accumulation of IL17-secreting CD4+ T cells or of CD11b+ cells was found in joints of TS1xHACII mice that
had developed arthritis, despite having received anti-TNF treatment.
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Thus, the ability of anti-TNF treatment to prevent arthritis development in
TS1xHACII mice was strongly associated with a reduced accumulation of Th17 cells and
CD11b+ cells specifically in the joints, since the representation of Th17 cells in the jdLNs
and spleens of these mice was relatively unaffected.

4.2.9 Anti-TNF treatment can modulate arthritis severity in TS1(SW)xHACII mice

Although the elimination of B cells was able to significantly reduce disease
penetrance in TS1(SW)xHACII mice, we nonetheless wanted to explore whether the
neutralization of TNF could also ameliorate disease development in this system.
Utilizing the same treatment protocol that was performed in TS1xHACII mice, we treated
pre-arthritic TS1(SW)xHACII mice with either an anti-TNF mAb or an isotype control
antibody (Fig. 4-11a). At 14 weeks of age, disease penetrance and severity of anti-TNF
treated TS1(SW)xHACII mice was not significantly different from isotype control-treated
mice (Fig. 4-11b). Surprisingly, the arthritis that develops in isotype control-treated
TS1(SW)xHACII mice scored noticeably lower than in untreated TS1(SW)xHACII mice,
although disease penetrance in these two sets of mice were very similar. This seems to
only occur in the TS1(SW)xHACII system as the severity of disease observed in
untreated and isotype control-treated TS1xHACII mice was not noticeably different (data
not shown). By 22 weeks of age, the apparent suppressive effect of the isotype control
antibody on disease severity in TS1(SW)xHACII mice seemed to have been overcome.
On the other hand, the arthritis scores for anti-TNF treated TS1(SW)xHACII mice at 22
weeks of age remained largely unchanged from when the mice were 14 weeks of age
but were significantly lower than the arthritis scores for both age-matched isotype
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control-treated and untreated TS1(SW)xHACII mice. Although the penetrance of disease
in anti-TNF treated mice did not significantly differ relative to both isotype control-treated
or untreated TS1(SW)xHACII mice at 14 and 22 weeks of age, we must point out that of
the anti-TNF treated mice that did develop disease, the majority displayed mild swelling
in only one paw (arthritis score of 1).

As previously described, a successful response to anti-TNF treatment can be
associated with increased frequencies and/or activity of Foxp3+ Tregs (Ehrenstein et al.
2004, Valencia et al. 2006, Nie et al. 2013). Therefore, similar to how Tregs in
TS1xHACII mice were analyzed, we examined whether the ability of anti-TNF treatment
to modulate disease in the TS1(SW)xHACII model system was through Tregs.
Comparable to the findings in TS1xHACII mice, anti-TNF treatment did not seem to
enhance either the representation or functionality of Tregs in TS1(SW)xHACII mice (Fig.
4-11c and d).

Collectively, these data demonstrate that anti-TNF treatment was able to
attenuate but not block arthritis development in TS1(SW)xHACII mice. Notably, the
ability of anti-TNF treatment to suppress disease development in TS1(SW)xHACII mice
was not as robust as in TS1xHACII mice since anti-TNF treated TS1(SW)xHACII mice
developed disease with reduced severity, but nonetheless, developed disease. Thus,
unlike in the TS1xHACII model, TNF in the low affinity system does not appear required
for diseased initiation. The modulation of arthritis development in anti-TNF treated (and
isotype control-treated) TS1(SW)xHACII mice did not seem to be due to an enhanced
Treg population.
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4.2.10 Anti-TNF treatment exerted systemic and local effects in TS1(SW)xHACII
mice

In an attempt to elucidate what may lead to the attenuation of disease in antiTNF treated TS1(SW)xHACII mice, we examined the representation of B cells and Th17
cells as both were previously shown to be associated with disease development in this
model system. The cellularity of LNs draining the joints in anti-TNF treated
TS1(SW)xHACII mice were significantly smaller than in isotype control-treated mice, but
this effect did not repeat with splenic cellularities (Fig. 4-12a). Notably, we did not find
lower frequencies of either total or clonotypic CD4+ T cells but did find significantly lower
frequencies of CD19+ B cells in anti-TNF treated mice relative to isotype control-treated
mice (Fig. 4-12b and c). The reduction of B cells was restricted to the jdLNs. We also
examined the representation of total and clonotypic CD4+ T cells capable of producing
cytokines, despite that the overall frequencies of these T cell populations were
unchanged in TS1(SW)xHACII mice after anti-TNF treatment. Although there were
lower frequencies of IL-17+ cells within the total CD4+ T cell population in
TS1(SW)xHACII mice treated with anti-TNF, the change that has consistently correlated
with disease attenuation in the TS1(SW)xHACII model system (reduced clonotypic Th17
cells) was not observed here (Fig. 4-12c).

To complete our analysis, we examined the immune cell populations in the joints
of anti-TNF treated and isotype control-treated TS1(SW)xHACII mice. Similar to what
was observed in mice from the high affinity model system following treatment with antiTNF, mice from the low affinity model system contained lower overall numbers of cells,
lower frequencies of CD11b+Gr-1+ neutrophils, and lower frequencies of IL-17+CD4+ T
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cells in the joints following anti-TNF treatment (Fig. 4-13a and b). The frequencies of
CD19+ B cells and of IFN-+CD4+ T cells were unaffected by anti-TNF treatment;
although modest, the reduced frequency of CD4+ T cells in anti-TNF treated mice was
statistically significant.

Collectively, these data show that although anti-TNF treatment reduced B cells
and Th17 cells in the jdLNs and significantly prevented the accumulation of neutrophils
and Th17 cells in the joints, disease still developed in treated TS1(SW)xHACII mice.

4.2.11 IL-17 can support B cells in TS1(SW)xHACII mice

In light of the findings demonstrating that IL-17 can support autoreactive germinal
center B cells in the K/BxN and BXD2 mouse model systems of inflammatory arthritis
(Hsu et al. 2008, Wu et al. 2010), we examined if B cells were altered in anti-IL-17R
treated TS1(SW)xHACII mice. Indeed, serum IgG concentrations were significantly
reduced in anti-IL-17R treated mice relative to isotype control-treated mice (Fig. 4-14a).
Serum IgG titers in anti-IL-17R treated TS1(SW)xHACII mice were reduced to the point
where they were comparable to the levels found in control TS1(SW) mice. Moreover, we
found that the frequency and absolute numbers of total CD19+ B cells were significantly
reduced in the jdLNs of anti-IL-17R treated mice, whereas the frequency and absolute
numbers of CD11c+ DC, another APC population, appeared unaffected (Fig. 4-14b and
c). Notably, CD19+ B cells were only reduced in the jdLNs but not the spleens of
TS1(SW)xHACII mice following anti-IL-17R treatment. It is generally accepted that IL-17
participates in the maturation and recruitment of neutrophils
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(Lubberts et al. 2005, Kolaczkowska and Kubes 2013). This could explain why we also
found significantly lower frequencies and absolute numbers of CD11b+ cells (which were
largely neutrophils, data not shown) in anti-IL-17R treated TS1(SW)xHACII mice.

These results led us to question whether B cells and CD11b+ myeloid cells in
TS1(SW)xHACII mice express the receptor for IL-17: IL-17RA (Gaffen 2009).
Consistent with published reports, we found IL-17RA expressed on multiple cell types
including, but not limited to, CD11b+/Gr-1+ cells, B220+ B cells, germinal center B cells,
and CD138+ plasma B cells (Fig. 4-15). Although we found fewer B cells in the jdLNs
(but not in the spleens) of TS1(SW)xHACII mice after anti-IL-17R treatment, we did not
find a higher fraction of B cells expressing the IL-17 receptor in the jdLNs compared to
the spleens.

Collectively, these data show that blockade of IL-17 signaling significantly
prevented the accumulation of systemic IgG, CD19+ B cells, and CD11b+ cells in
TS1(SW)xHACII mice. Moreover, we showed that CD11b+ and B cells can express the
IL-17 receptor. Thus, these data suggest that IL-17 can directly support B cells and
CD11b+ myeloid cells in TS1(SW)xHACII mice. Importantly, these data also suggest
that Th17 cells and B cells may have reciprocal roles in supporting each other leading up
to the development of inflammatory arthritis in the low affinity model system. However,
we recognize that anti-IL-17R treatment could have modulated other factors known to
stimulate or maintain B cells (such as BAFF or IL-6) (Mackay and Ambrose 2003) and
neutrophils (such as G-CSF or IL-8) (Kolaczkowska and Kubes 2013).
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4.2.12 Assessment of soluble factors and immune cell subsets in non-arthritic
TS1(SW)xHACII mice

Based on our current findings, we believe we have identified some factors and
cellular populations (mainly IL-17/Th17 cells, B cells and TNF) that are involved in the
pathogenesis of disease in TS1(SW)xHACII mice. From this stance, we examined male
and female TS1(SW)xHACII mice that did or did not develop arthritis (refer to Fig. 3-3d).
Notably, non-arthritic female TS1(SW)xHACII mice contained significantly lower levels of
IL-17 and moderately lower levels of IL-6, IL-1B and IFN- relative to females that were
arthritic, while IgG titers were not significantly different (Fig. 4-16a and b). Although the
jdLNs of non-arthritic female mice were moderately smaller than those from arthritic
female mice, no significant differences were found in the percentages of CD4+ T cells
(either total or those expressing the clonotypic TCR), of CD4+CD25+Foxp3+ cells, of
CD4+IL-17+ cells, or of B cells in the jdLNs between arthritic and non-arthritic females
(Fig. 4-16c).

Inflammatory cytokine levels, IgG titers, and jdLN cellularities were found to be
higher in female TS1(SW)xHACII mice that had developed arthritis compared to arthritic
male TS1(SW)xHACII mice, consistent with the more severe inflammatory processes
affecting the joints of female versus male TS1(SW)xHACII mice (Fig. 3-4b). We did not
find significant difference between the representation of immune cell populations
between arthritic male and female mice. It was striking in this analysis, however, that
arthritic male mice were in many respects not different from non-arthritic male mice.
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Along the same lines, male arthritic mice were not significantly different from female nonarthritic mice, except for possibly the percentage of CD4+IL-17+ cells.

We performed these analyses in arthritic and non-arthritic, male and female
TS1(SW)xHACII mice in an attempt to find correlates to the absence of disease
development. However, the results from these analyses did not yield any clear-cut
answers. The overall extent of systemic immune activation was noticeably lower in nonarthritic females compared to arthritic females. However, it is harder to explain the lack
of differences between arthritic and non-arthritic males and also between non-arthritic
females and males with or without disease. Perhaps comparisons must be run with
multiple factors in consideration. Another possibility is that we did not account for other
factors at play in this system. Some studies have tried to account for the increased
prevalence of autoimmune diseases in females compared to males and have attributed
this to the effect of sex hormones. Estrogen appears to be immunostimulatory whereas
testosterone appears immunosuppressive and men who develop RA were found to have
higher levels of estrogen and low levels of testosterone (Roden et al. 2004, ZandmanGoddard et al. 2007, Quintero et al. 2012). Because disease develops with a female
bias in this model system, the level of female sex hormones (or even the balance
between female and male sex hormones) may also factor into whether one littermate
develops disease compared to the other and the differences observed between female
and male TS1(SW)xHACII mice.
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4.3 Discussion

In the previous chapter, we clearly demonstrate that the affinity with which an
autoreactive CD4+ T cell recognizes a single target autoantigen not only dictates the
extent of arthritis development but also the degree of systemic immune activation. In
this chapter, we wanted to explore whether the effect of varying an autoreactive CD4+ T
cell response extends past affecting disease susceptibility to also influence the pathways
by which disease develops in TS1xHACII and TS1(SW)xHACII mice.

As previously reported (Rankin et al. 2008) and repeated here, B cells are not
required for arthritis development in TS1xHACII mice. This was surprising since
TS1xHACII mice contained B cells exhibiting an activated phenotype (Rankin et al.
2008) and contained elevated levels of serum IgG, more so than in TS1(SW)xHACII
mice (Fig. 3-10b). The extent of B cell activation in TS1xHACII mice seems to reflect the
affinity with which autoreactive CD4+ T cells recognize the S1 self-antigen presented by
B cells, leading to reciprocal activation and help for B cells to class switch (Rankin et al.
2008). Nonetheless, it appears that the presentation of the S1 self-peptide by other APC
subsets in this system was sufficient to drive disease. Not only are B cells and their
products dispensable for disease initiation in TS1xHACII mice, they do not seem to be
required to perpetuate disease as disease develops with similar penetrance and severity
in TS1xHACII.JH-/- and TS1xHACII mice. Interestingly, disease onset was markedly
accelerated in TS1xHACII.JH-/- mice, which suggests that B cells in this system may play
a protective role. Indeed, B cells have a newly appreciated regulatory role: a subset of
B cells capable of producing IL-10 (termed Bregs) have been identified and shown
capable of down-modulating the extent of systemic activation in several settings
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(Fillatreau et al. 2002, Mizoguchi et al. 2002, Mauri et al. 2003). Thus, it may be of
interest to examine if pre-arthritic TS1xHACII mice contain Bregs or if disease can be
modulated with transfer of Bregs or IL-10.

Unlike some other models of inflammatory arthritis (Stuart and Dixon 1983,
Korganow et al. 1999, Hsu et al. 2008), the requirement for B cells in TS1(SW)xHACII
mice did not appear to reflect a prominent contribution of arthritogenic antibodies.
Autoantibody specificities associated with arthritis in other settings (Hueber et al. 2005,
McInnes and Schett 2011) were not elevated in the serum of TS1(SW)xHACII mice
relative to TS1xHACII and control TCR single transgenic mice. Moreover, unlike serum
isolated from K/BxN mice, serum from arthritic TS1(SW)xHACII mice did not transfer
disease. Also in line with this supposition, “semi-depleted” anti-CD20 treated
TS1(SW)xHACII mice (where B cell depletion was incomplete and so elevated levels of
serum IgG were still found in these mice) did not develop arthritis, whereas a few antiCD20 treated mice (containing little to no serum IgG) did develop arthritis. We
understand, however, that these findings are circumstantial and cannot completely rule
out a role for antibodies in this model system. Although we performed ELISAs to detect
autoantibody specificities associated with arthritis, we may have not examined the right
specificity, for example, anti-GPI - the pathogenic antibody specificity in K/BxN mice
(Korganow et al. 1999). It is also possible that serum from arthritic TS1(SW)xHACII
mice is able to transfer disease, but since the concentration of arthritogenic
immunoglobulin(s) is low, not enough was transferred in the experiments previously
performed. Notably, provision of TS1(SW)xHACII mice with an exogenous antibody (an
isotype control IgG2a mAb) was able to delay (but not prevent) disease progression. In
line with this observation, a therapy developed for some autoimmune disorders, called
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IVIG, involve the transfer of exogenous polyclonal IgG into the patient (Pyne et al. 2002,
Siberil et al. 2007). Several proposed mechanisms exist for how IVIG works; one of
these is that the exogenous IgG saturates activating Fc receptors, limiting the binding of
endogenously created immune complexes. Therefore, it would be interesting to
examine the amount of immune complexes before and after isotype control-treatment.
Also, since each IgG subclass binds and triggers Fc receptors differently, it might of
interest to investigate the concentrations of each subclass of IgG in TS1(SW)xHACII
mice. Because the contribution of antibodies to disease development in
TS1(SW)xHACII mice remains unclear, we propose that an experiment better designed
to probe the contribution of autoantibodies would be to cross TS1(SW)xHACII mice with
the mIgM mouse developed by Mark Shlomchik in which B cells express but do not
secrete their B-cell receptor as soluble immunoglobulin (Chan et al. 1999). Of note, B
cells in mIgM mice express a limited BCR repertoire as these mice were generated with
a fixed VH transgene. Thus, B cells in mIgM mice should be capable of presenting
internally synthesized peptides complexed with MHCII on their surface normally but will
have a limited capability to uptake and present external peptides. Results from these
experiments should, therefore, be interpreted carefully.

Rather than act as a source of pathogenic autoantibodies, B cells appear to
contribute to disease development in TS1(SW)xHACII mice by participating as APCs for
Th17 cells expressing the autoreactive V8.3/V10 TCR. In B cell deficient
TS1(SW)xHACII mice, significantly reduced frequencies of clonotypic Th17 cells was
associated with the absence of disease development. Since B cells represent a large
APC population, removal of this population would remove a large source of S1 antigen.
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Therefore, although the overall representation of clonotypic CD4+ T cells was not
significantly different in B cell deficient and B cell sufficient TS1(SW)xHACII mice, it is
possible that limited access to antigen can result in a reduced ability of CD4+ T cells to
differentiate into the Th17 lineage. However, it is also possible that B cells in this system
act as unique APCs for the generation of IL-17+V8.3+V10+ CD4+ T cells. This is
interesting because S1 expression in HACII mice is directed to all MHCII+ APCs (Reed
et al. 2003). Nonetheless, these results suggest that the expression of the S1 selfantigen specifically on B cells is important in supporting the development of pathogenic
Th17 cells. Although several studies have highlighted the unique contribution of B cells
as APCs in several settings (including autoimmunity) (Chan et al. 1999, O'Neill et al.
2005, Crawford et al. 2006, Hamel et al. 2008, Wilson et al. 2012), not much is known on
how B cells can specifically support Th17 cells (Hamel et al. 2008, van de Veerdonk et
al. 2011, Wang and Rothstein 2012). Therefore, these studies demonstrate a unique
finding that B cells, expressing a known target autoantigen, can play an essential role in
the differentiation of autoreactive CD4+ T cells into the Th17 lineage.

Interestingly, B cells and Th17 cells may play reciprocal roles in supporting each
other in TS1(SW)xHACII mice. In B cell deficient mice, lower frequencies of clonotypic
Th17 cells were found; in anti-IL-17R treated mice, lower frequencies of B cells (and
serum IgG concentrations) were found. Notably, CD19+ B cells were only reduced in the
jdLNs, but not the spleens, of TS1(SW)xHACII mice following anti-IL-17R treatment.
The expression of IL-17RA, however, was not limited to B cells in the jdLNs or
specifically upregulated by B cells in the jdLNs. These pieces of data together suggest
that IL-17 can directly support B cells in the jdLNs of TS1(SW)xHACII mice. Moreover,
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these data imply that IL-17 may be a necessary factor for jdLN-associated B cells but
other survival/growth factors (such as BAFF and IL-6) (Mackay and Ambrose 2003) can
compensate for the absence of IL-17 signaling in splenic B cells. Interestingly, these
results recapitulate findings in other mouse models of inflammatory arthritis whereby B
cells significantly contribute to disease pathogenesis (Stuart and Dixon 1983, Korganow
et al. 1999, Hsu et al. 2008).

Neutralization of TNF was able to significantly ameliorate arthritis development in
TS1xHACII mice but only able to modulate disease severity in TS1(SW)xHACII mice. It
was apparent that the ability of anti-TNF treatment to suppress disease in TS1xHACII
mice was much more pronounced. The available literature examining the contribution of
TNF in inflammatory arthritis is expansive and exemplifies the pleiotropic role the
cytokine can play during disease development (Feldmann 2002). However, in
TS1xHACII mice, anti-TNF treatment was not found to modulate serum cytokines levels,
increase the representation/functionality of Tregs, or even prevent the differentiation of
Th1/Th17 cells. Instead, in anti-TNF treated mice that did not develop disease
(protected mice), the accumulation of Th17 and CD11b+ neutrophils in the joints was
prevented. Taking into account that TNF has been shown capable of inducing the
expression of CCL20 (the ligand for CCR6) in synoviocytes (Chabaud et al. 2001, Hirota
et al. 2007), we propose the following mechanism by which TNF contributes to arthritis
development in TS1xHACII mice: TNF, possibly working in concert with IL-1B and IL-17,
induces joint-associated synoviocytes to upregulate the production of the chemokine
CCL20. This in turn attracts Th17 cells bearing the receptor for CCL20, CCR6. Lastly,
IL-17 secreted by Th17 cells that have accumulated in the joints may then attract
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neutrophils capable of joint destruction. Thus, TNF appears to play a specific and
possibly limited role in promoting arthritis development in TS1xHACII mice.

In anti-TNF treated TS1(SW)xHACII mice, we observed lower frequencies of B
cells and IL-17+ CD4+ T cells in the secondary lymphoid organs. Moreover, anti-TNF
treatment significantly prevented the accumulation of neutrophils and Th17 cells in the
joints, similar to what occurred in anti-TNF treated TS1xHACII mice. It is unclear
whether the reductions in B cells and Th17 cells seen in the jdLNs and spleens of antiTNF treated mice are required for disease attenuation in this system or whether they
were a bystander consequence of a reduced inflammatory response in the mouse.
Despite both systemic and local effects of the anti-TNF mAb, disease still developed in
the majority of treated mice. Interestingly, although the recruitment of neutrophils and
Th17 cells were significantly prevented in anti-TNF treated TS1(SW)xHACII mice, the
majority of them still developed at least one swollen limb. This suggests that TNF may
play an additional role besides that of recruiting cells into the joints in this model system,
which is in contrast with what is found in TS1xHACII mice. It is possible, in this setting,
that other pro-inflammatory cytokines such as IL-6 or IL-1 can produce a low grade
inflammation in the absence of TNF, but TNF is necessary to synergize and perpetuate
inflammation to progress inflammatory arthritis. If this is the case, it would suggest that
TNF exerts multiple modes of action to drive inflammatory arthritis in TS1(SW)xHACII
mice.

Thus, we believe we have demonstrated that the degree of CD4+ T cell reactivity
for self-peptide can play a prominent role in determining the cellular pathways that
participate in the development of inflammatory arthritis. Through analysis of B cell
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deficient mice and mice treated with various anti-cytokine antibodies, we have shown
that TNF, but not B cells, is required for arthritis development in the TS1xHACII model
system. This suggests that B cells are not necessary to either promote or act as a target
of TNF in this model system. On the other hand, B cells significantly contribute to
disease development in TS1(SW)xHACII mice; TNF appears to contribute to enhancing
disease severity in this model but is not required for disease initiation. Thus, pathways
by which disease develops in TS1xHACII and TS1(SW)xHACII mice are fundamentally
different.

As shown very early on in Chapter 3, mice generated with the low affinity TCR for
the S1 self-peptide (TS1(SW)xHACII mice) develop disease with a female bias.
Interestingly, how disease develops in this low affinity model system is better at
recapitulating RA development in humans (women develop RA 3 times more frequently
than men) (Quintero et al. 2012). The sex bias observed in TS1(SW)xHACII mice
suggests that gender-associated factors such as sex hormones may play a role in this
model system. Indeed, in DR4.AEo mice (a humanized HLA-DR4 mouse model of
induced inflammatory arthritis), arthritis develops with a female bias, but this bias was
largely overcome when males were castrated, implicating the protective role of male
hormones (Behrens et al. 2010). Additionally in the NZBXNZW F1 model of lupus,
which develops lupus with a strong female bias, treatment with tamoxifen (an estrogen
receptor modulator) attenuates disease in female mice (Sthoeger et al. 2003).
Therefore, these findings suggest that the extent of the CD4+ T cell autoreactive
response to self-antigens can also dictate the contribution of sex hormones in disease
development.
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Tregs constitute an important mechanism of peripheral tolerance induction and
therefore are studied extensively in autoimmune disease settings (Sakaguchi et al. 2008,
Shevach 2009). Because of this, we found it surprising that arthritic TS1xHACII and
arthritic TS1(SW)xHACII mice contained high frequencies of CD4+ T cells expressing
CD25 and Foxp3; moreover, the expression levels of CD25 and Foxp3 were not
abnormal in arthritic mice compared to control mice. Furthermore, CD4+CD25+ Tregs
isolated from arthritic mice of both lineages suppressed just as well as BALB/c Tregs
when their functionality was compared side-by-side in in vitro suppression assays. From
the studies performed in this chapter, the modulation of disease following treatment in
each model system did not associate with an apparent enhancement in the
representation or function of Tregs. It is possible that the suppression assays we
performed were unable to reveal a difference (either supporting or negating Treg
functionality) since we used anti-CD3 to stimulate both responders and Tregs or that the
ratios of Tregs to responders used were not physiologically representative. It is also
possible that effector T cells in these model systems are resistant to Treg suppression.
We do not believe this to be the case since the transfer of polyclonal Tregs from wildtype mice can ameliorate disease development in both TS1xHACII and TS1(SW)xHACII
mice ((Oh et al. 2012) and data not shown). Lastly, it is possible that Tregs in these two
systems are not appropriately “polarized”. Recent work has demonstrated that for
efficient suppression of CD4+ T cells of a certain T helper lineage, Tregs should adopt
the same transcription factor profile (Campbell and Koch 2011). Because of this, it
would be interesting to examine if we can find the presence (or lack of) Tregs in
TS1xHACII and TS1(SW)xHACII mice that display a Th-17-like phenotype or enhanced
STAT3 signaling (Chaudhry et al. 2009, Duhen et al. 2012). The data we show here,
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however, suggest that the modulation of Tregs is not a requirement for treatment
regimens to work in TS1xHACII or TS1(SW)xHACII mice.

In summary, the studies performed in this chapter demonstrate that the overall
reactivity of the CD4+ T cell response to a ubiquitously expressed self-peptide can play a
prominent role in determining the cellular pathways that participate in the development of
inflammatory arthritis. In TS1xHACII mice, an autoreactive CD4+ T cell response to the
S1 self-peptide was measurable in an autologous MLR, and serum in these mice
contained elevated levels of both pro-inflammatory cytokines and immunoglobulin.
While arthritis development could be prevented by the anti-cytokine treatments (namely
anti-IL-17 and anti-TNF), it was not affected by B cell elimination. By contrast, serum
cytokine levels were lower in TS1(SW)xHACII mice in a setting whereby the peripheral
CD4+ T cell repertoire was less responsive to the S1 self-peptide, and in this case,
elimination of B cells significantly suppressed arthritis development but TNF
neutralization only affected the severity with which disease develops. Notably, both antiTNF treatment and B cell elimination appeared to prevent arthritis development in these
two models at least in part by disrupting Th17 cell activity, albeit by distinct mechanisms.
Collectively, these studies demonstrated that fundamentally different pathways of
pathogenesis exist in TS1xHACII and TS1(SW)xHACII mice which can be attributed to
the inherent reactivity of CD4+ T cells in response to self-antigen in each model system.
This may explain why therapies targeting distinct pathways have different efficacies in
different patients.
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Chapter 5: Discussion and Speculation

+

5.1 Impact of CD4 T cell affinity on the development of inflammatory arthritis

It is well established that CD4+ T cells can significantly contribute to the
development of autoimmune arthritis. Numerous studies examining the roles of CD4+ T
cells in autoimmune settings emphasize their extensive capabilities to initiate and
maintain disease. To elaborate their effector function(s), autoreactive CD4+ T cells must
first be stimulated through their TCR. The spontaneous development of inflammatory
arthritis in mice engineered to co-express a transgenic TCR with a known target
autoantigen (like K/BxN and TS1xHACII mice) and the induced development of arthritis
in mice with certain MHCII alleles (like CIA and PGIA), highlight the importance of
antigen recognition by CD4+ T cells in the appropriate context in order to incite
autoimmunity. Therefore, our studies were aimed at examining how CD4+ T cell
recognition of a known, target autoantigen can shape the development of inflammatory
arthritis. We performed these studies using the TS1xHACII mouse model of arthritis
(Rankin et al. 2008) as our basis; we then modified the affinity of the transgenic TCR for
the fixed target autoantigen to generate TS1(SW)xHACII mice. Briefly, TS1xHACII mice
were generated to co-express PR8 HA as a surrogate self-antigen and a transgenic TCR
that recognizes the S1 determinant of PR8 HA as a cognate antigen (Fig. 3-1a). We
then fixed the autoantigen (PR8 S1) but changed the transgenic TCR that was coexpressed into one that recognizes S1 with low affinity to generate TS1(SW)xHACII
mice (Fig. 3-3a). We demonstrated in Fig. 3-2 that the TS1(SW) TCR does indeed
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recognize the S1 antigen expressed in HACII mice with low affinity. In using these two
variant model systems – TS1xHACII and TS1(SW)xHACII mice – we could begin to
assess how a CD4+ T cell response to a single target antigen can influence inflammatory
arthritis development.

Overall assessment of TS1xHACII and TS1(SW)xHACII mice revealed that both
of these lineages were capable of developing overtly identifiable manifestations of
inflammatory arthritis (Fig. 3-1b and 3-3b). The elaboration of a destructive jointtargeted disease in these mice was further confirmed by histology (Fig. 3-4).
Interestingly, although mice from both TS1xHACII and TS1(SW)xHACII lineages were
found to display swollen paws, a female bias emerged in cohorts of TS1(SW)xHACII but
not TS1xHACII mice (Fig. 3-1c and Fig. 3-3d). Not only did fewer male TS1(SW)xHACII
mice develop disease, they also exhibited a significant delay in disease onset.
Additionally, joint sections from male TS1(SW)xHACII mice that did develop disease
scored significantly lower for synovitis and articular degeneration compared to arthritic
female mice. These findings demonstrate that the affinity with which CD4+ T cells
recognize a single target antigen can clearly influence the development of inflammatory
arthritis with regard to disease penetrance and severity.

In both TS1xHACII and TS1(SW)xHACII mice, CD4+ T cells bearing the
autoreactive TCR were subjected to thymic deletion; however, central tolerance was
incomplete as a subset of these cells can be found in the LNs and spleens of both sets
of mice (Fig. 3-2d and Fig. 3-6). The clonotypic CD4+ T cells that managed to escape
thymic deletion appeared activated and capable of producing inflammatory cytokines
(Fig. 3-6 and Fig. 3-9). If we just used these readouts as a measurement of their
127

autoreactivity, one might roughly estimate that the overall effector contribution of
6.5+CD4+ and V8.3+CD4+ T cells in each respective system might be comparable. This
is taking into account that both 6.5+CD4+ and V8.3+CD4+ T cells expressed markers of
antigen experience at levels higher than control mice (although these were generally
higher on 6.5+CD4+ T cells than on V8.3+CD4+ T cells) and that subsets of both
6.5+CD4+ and V8.3+CD4+ T cells appeared capable of producing IFN- or IL-17 (the
percentages of which were not dramatically dissimilar). However, from performing an
autologous MLR, we discovered that CD4+ T cells isolated from TS1xHACII mice were
appreciably more autoreactive than CD4+ T cells isolated from TS1(SW)xHACII mice
(Fig. 3-7). It appears that the autoreactive CD4+ T cells that managed to escape thymic
deletion in TS1xHACII mice maintained a relatively high level of reactivity as compared
to those from TS1(SW)xHACII mice. In line with this finding, the extent of systemic
activation (as determined by systemic cytokine levels and IgG titers) in TS1xHACII mice
was not only considerably higher than in TS1(SW)xHACII mice, it was extensive (Fig. 310). A wide range of cytokines were elevated in the serum of TS1xHACII mice, derived
from both T cells and non-T cells. Additionally, TS1xHACII mice contained significantly
higher concentrations of IgG than both control and TS1(SW)xHACII mice. These results
suggest that the affinity of the T cell-APC interaction, and the subsequent downstream
effects of this (i.e. production of cytokines and chemokines that activate surrounding
immune and non-immune cells) directly influences the extent of systemic immune
activation (Ahlers et al. 2001, Diepolder et al. 2001). Thus, not only does the affinity with
which autoreactive CD4+ T cells recognize a single target antigen influence arthritis
susceptibility, there exists a positive correlation with how it affects the extent of systemic
immune activation.
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Our last major finding in assessing TS1xHACII and TS1(SW)xHACII mice was
that differential, and shared, pathways of disease pathogenesis exist between these two
models. Briefly, the pro-inflammatory cytokines lL-17 (Oh et al. 2012) and TNF were
important for disease development in TS1xHACII mice, whereas B cells and their
products were not required (Fig. 4-7b and Fig. 4-1a). IL-17 was also required for
disease development in TS1(SW)xHACII mice (Fig. 3-11a); TNF appeared to influence
the severity with which disease develops in this system but seemed unnecessary for
disease initiation (Fig. 4-11b). Strikingly, in the context of a low affinity, autoreactive
TCR, B cells were found necessary for arthritis to develop in TS1(SW)xHACII mice (Fig.
4-1b). A more detailed analysis of how we think each factor promotes disease in
TS1xHACII and TS1(SW)xHACII mice will be discussed in the following sections.
Collectively, our findings reveal that the pathways by which disease develops in
TS1xHACII and TS1(SW)xHACII mice are profoundly different, demonstrating the
prominent influence that the degree of CD4+ T cell autoreactivity has on directing the
pathways by which inflammatory arthritis develops.

The comparison of serum cytokine levels and serum IgG titers in arthritic
TS1xHACII and TS1(SW)xHACII mice were immediately surprising to us (Fig. 3-10).
Not in part because these results positively correlated with the autoreactivity of CD4+ T
cells found in each system, but that these two sets of mice, which developed a very
similar form of autoimmune disease, displayed such a profoundly different systemic
profile. Arthritic TS1xHACII mice contained elevated levels of a variety of cytokines,
which was largely absent in arthritic TS1(SW)xHACII mice. Additionally, although
elevated levels of IgG were found in the serum of TS1(SW)xHACII mice compared to
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controls, even higher levels were observed in TS1xHACII mice. These results suggest
that overt systemic inflammation is not a requisite for inflammatory arthritis development.
Indeed, blockade of a single cytokine (IL-17 in particular) can ameliorate arthritis onset in
both TS1xHACII and TS1(SW)xHACII mice ((Oh et al. 2012) and Fig. 3-11a)). However,
we cannot rule out the possibility that in these two model systems, IL-17 sits at the top of
a cytokine cascade or that IL-17 can drive arthritis development by different means. It
may be worthwhile to assess the serum cytokine profiles of anti-IL-17/anti-IL-17R treated
mice. Strikingly, B cells and their products were not required for arthritis to develop in
TS1xHACII mice (Fig. 4-1a), despite containing B cells with an activated phenotype and
exhibiting hypergammaglobulinemia ((Rankin et al. 2008) and Fig. 3-10b)). Collectively,
these results argue that, although high affinity CD4+ T cells upon recognition of selfantigen can elicit extensive systemic immune activation, this may not be required for the
development of inflammatory arthritis.

Historical work examining TCR stimulation strength and effects on T cell fate
demonstrated that high affinity CD4+ T cells were eventually deleted or anergized
following activation and proliferation (Oki and Sercarz 1985, Forster et al. 1995, Rocha
et al. 1995, Yamamoto et al. 2007). Similarly with CD8+ T cells, high amounts of antigen
promote T cell exhaustion (Wherry et al. 2003). Therefore, it might be surprising that
TS1xHACII mice, which contain a high affinity TCR for self-antigen, develops a more
severe form of autoimmunity than TS1(SW)xHACII mice. However, we must take into
consideration that the highest self-reactive clones were most likely deleted in the thymus
before entering the periphery since CD4+ T cells were found to express low 6.5 TCR
surface densities (Rankin et al. 2008). These observations were reasoned to not be a
virtue of allelic inclusion as the CD4+ T cells that escape negative selection to be found
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in the periphery of TS1xHACII.RAG-/- mice (in which only the transgenic TCR can be
expressed) also express low 6.5 TCR surface densities. Moreover, the overall reactivity
of HA-specific CD4+ T cells found in the periphery of TS1xHACII mice was considerably
reduced compared to HA-specific CD4+ T cells isolated from TS1 mice (where TS1 T
cells have not experience their cognate antigen) (compare Fig. 3-2d to Fig. 3-7). Thus,
reduced TCR levels allowed for self-reactive 6.5+CD4+ T cells to escape negative
selection in TS1xHACII mice, and possibly have allowed them to escape peripheral
mechanisms of tolerance such as deletion or functional anergy.

5.2 Cellular pathways underlying arthritis development dictated by the extent of
+

CD4 T cell autoreactivity in TS1xHACII and TS1(SW)xHACII mice: Updated
working models

From our findings in B cell deficient and anti-cytokine treated mice, we have
constructed working models of how various factors and cellular populations contribute to
the pathways of pathogenesis in TS1xHACII and TS1(SW)xHACII mice (Fig. 5-1).

The current working model for how disease develops in TS1xHACII mice has
been cultivated through work performed by previous lab members (Rankin et al. 2008,
Oh et al. 2012, Simons et al. 2013) and from work performed in this thesis. In the thymii
of TS1xHACII mice, CD4+ T cells bearing the clonotypic TCR recognize the S1 selfantigen with high affinity and are thus subjected to extensive thymic deletion. However,
central tolerance is incomplete as we can find a small population of 6.5+CD4+ T cells in
both the LNs and spleens of young, pre-arthritic TS1xHACII mice. These high affinity,
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autoreactive 6.5+CD4+ T cells then interact with HA-expressing APCs, leading to the
reciprocal activation of both T cells and APCs. Activated B cells proceed to differentiate
into plasma cells and secrete high levels of IgG. We believe the T cell-APC interaction
in TS1xHACII mice also promote the development of Th17-trophic inflammatory
monocytes which may induce the formation of pathogenic Th17 cells. Indeed, arthritis in
this system develops by an IL-17-dependent mechanism as blockade of this cytokine
significantly abrogates disease onset. Furthermore, disease onset in these mice could
also be significantly blocked by anti-TNF treatment, but not by B cell elimination, despite
containing activated B cells and high serum titers of IgG. Examination of arthritic and
non-arthritic anti-TNF treated TS1xHACII mice revealed that protection from disease
development did not appear to be due to the treatment’s ability to inhibit the production
of inflammatory cytokines or the formation of Th1 and Th17 cells. Instead, in positive
responders, anti-TNF treatment appears to prevent the specific accumulation of Th17
cells in the joints. We believe it is the accumulation of Th17 cells (whether through
recruitment or local proliferation) that anti-TNF treatment prevents and not their
formation since non-arthritic anti-TNF treated mice contained the same frequency of
Th17 cells in the jdLNs and spleens as arthritic anti-TNF treated mice. We postulate that
one mechanism by which TNF promotes disease in this model is by inducing
synoviocytes to express the chemokine CCL20 which then attracts pathogenic Th17
cells (Chabaud et al. 2001, Hirota et al. 2007). Joint-localized Th17 cells would in turn
secrete IL-17 to attract CD11b+ neutrophils capable of producing MMPs and reactive
oxygen species (ROS) that directly lead to cartilage and bone destruction
(Kolaczkowska and Kubes 2013).
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We next describe our working model for how disease develops in
TS1(SW)xHACII mice from results described in this thesis: Clonotypic CD4+ T cells
were also subjected to thymic deletion but were again found to populate the LNs and
spleens of young, pre-arthritic TS1(SW)xHACII mice. Most likely through interactions
with HA-expressing APCs, self-reactive CD4+ T cells in this system acquire an activated
phenotype and the ability to produce IFN- and IL-17. Notably, we found that disease
develops by an IL-17-depedent mechanism in this model system as well, similar to
TS1xHACII mice. However, in contrast to TS1xHACII mice, we found that B cells
significantly contributed to disease development in this low affinity model system.
Although elevated levels of serum IgG could be found in arthritic TS1(SW)xHACII mice
relative to control mice, we do not believe disease is driven in TS1(SW)xHACII mice by
arthritogenic autoantibodies. Instead, it appears that B cells function as APCs to
promote the formation of clonotypic effector CD4+ T cells. Notably, the absence of
disease in B cell deficient TS1(SW)xHACII mice was associated with a significant
reduction of clonotypic Th17 cells. Thus, our findings suggest that B cells may promote
arthritis development in TS1(SW)xHACII mice at least in part through an ability to
support the differentiation and/or accumulation of clonotypic Th17 cells. Moreover, we
found that TS1(SW)xHACII mice contained significantly fewer CD19+ B cells specifically
in the jdLNs following anti-IL-17R treatment and that B cells (among other immune cell
populations) in TS1(SW)xHACII mice can express the receptor for IL-17. Collectively,
these findings lead us to postulate that B cells and Th17 cells can directly support each
other to promote disease pathogenesis in this system. Lastly, we found that anti-TNF
treatment has disparate effects in TS1(SW)xHACII mice compared to TS1xHACII mice.
In striking contrast to TS1xHACII mice, arthritis onset was not prevented in anti-TNF
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treated TS1(SW)xHACII mice, although the severity of the disease that developed was
appreciably less severe relative to control mice (both isotype control-treated and
untreated TS1(SW)xHACII mice). Thus TNF neutralization was also capable of
modulating disease in TS1(SW)xHACII mice, but the therapeutic benefits of the
treatment in this system were less prominent than in the TS1xHACII system. Also in
contrast to TS1xHACII mice, effects were observed within the jdLNs in addition to the
joints of anti-TNF treated TS1(SW)xHACII mice. The accumulation of B cells and Th17
cells in the jdLNs and the accumulation of neutrophils and Th17 cells in the joints were
significantly reduced in TS1(SW)xHACII mice following anti-TNF treatment; whether
these events are causally related or not has not yet been determined. However, we
propose that in this setting anti-TNF treatment may prevent the accumulation of B cells
and Th17 cells in the jdLNs by possibly disturbing their reciprocal support network,
reducing the pool of Th17 cells available to be recruited to the joints. The multiple
effects of anti-TNF treatment observed in TS1(SW)xHACII mice, however, appeared
insufficient to completely prevent disease onset. It is possible, in this setting, that other
pro-inflammatory cytokines such as IL-6 or IL-1 can produce a low grade inflammation in
the absence of TNF which may be sufficient to initiate and maintain a mild form of
arthritis, but in the presence of TNF, synergize to enhance inflammation and the severity
of disease. If this is the case, it would suggest that TNF can play shared, but also
disparate, roles dictated by the context of the CD4+ T cell response to self-antigen.

Notably, TS1xHACII and TS1(SW)xHACII mice develop disease in the presence
of high frequencies of Tregs (Fig. 4-8a and Fig. 4-4a). We have previously
demonstrated that Tregs purified from arthritic mice are as capable as BALB/c Tregs in
suppressing the proliferation of responder cells in vitro (Fig. 4-8c and Fig. 4-4c).
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Moreover, we demonstrated that effective disease-suppressive manipulations performed
in either TS1xHACII or TS1(SW)xHACII mice (anti-TNF treatment and B cell elimination,
respectively) did not enhance Treg frequencies or Treg suppressor function (Fig. 4-4, 6,
8, 11). These results would suggest that disease in TS1xHACII and TS1(SW)xHACII
mice cannot be modulated through Tregs. In spite of this, we do not believe that to be
the case as provision of Tregs from wild-type BALB/c mice in into both TS1xHACII and
TS1(SW)xHACII mice can inhibit arthritis onset ((Oh et al. 2012) and data not shown).
This demonstrates that effector cells in TS1xHACII and TS1(SW)xHACII mice are
indeed able to be suppressed by Tregs, just not by the Tregs currently present in the
mouse. Thus, we believe that the development of arthritis in both TS1xHACII and
TS1(SW)xHACII mice is in part mediated by Treg insufficiency. We currently favor the
idea that endogenous Tregs found in each model system are insufficient at the
population level – that although seemingly “functional” on a per cell basis, they are
incapable of suppressing the particular autoimmune reaction that drives disease
development in TS1xHACII and TS1(SW)xHACII mice. Oh S et al. demonstrated that
transfer of polyclonal Tregs, but not HA-specific Tregs, can significantly ameliorate
disease onset in the TS1xHACII model system (Oh et al. 2012). These results suggest
that a diverse Treg repertoire is required for the successful suppression of arthritis
development in TS1xHACII mice. Therefore, it is possible that the reason why
endogenous Tregs cannot control disease in TS1xHACII and TS1(SW)xHACII mice is
because they do not express the appropriate TCR specificities, due to being limited by
the TS1 or TS1(SW) TCR transgenes. Although we favor this hypothesis, it is also
possible that endogenous Tregs in TS1xHACII and TS1(SW)xHACII mice are actually
dysfunctional on a per cell basis. We are currently determining Treg functionality
through use of an in vitro suppression assay which is in many respects an artificial
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simulation of what may occur in vivo. Indeed, the amount and duration of TCR signaling
as well as the exact environment (which is inflammatory in the case of TS1xHACII and
TS1(SW)xHACII mice) found in vivo cannot be replicated in vitro. Therefore, we cannot
completely rule out the possibility that Tregs in TS1xHACII and TS1(SW)xHACII mice
develop inflammatory arthritis due to dysfunctional Tregs or the possibility that effective
disease modulators work through bolstering Treg functionality.

In summary, we believe we have demonstrated that the degree of CD4+ T cell
reactivity for self-peptide can play a prominent role in determining the cellular pathways
that participate in the development of inflammatory arthritis. Through analysis of B cell
deficient mice and mice treated with various anti-cytokine antibodies, we have shown
that TNF, but not B cells, is required for arthritis development in the TS1xHACII model
system. This suggests that B cells are not necessary to either promote or act as a target
of TNF in this model system. On the other hand, B cells significantly contribute to
disease development in TS1(SW)xHACII mice; TNF appears to contribute to enhancing
disease severity in this model but is not required for disease initiation. Thus, pathways
by which disease develops in TS1xHACII and TS1(SW)xHACII mice are fundamentally
different.
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5.3 Speculation on how TCR affinity dictates the requirement for B cells in
TS1xHACII and TS1(SW)xHACII mice.

In this next section, we would like to speculate on how TCR affinity for a selfantigen might dictate the requirement for B cells for disease development in TS1xHACII
and TS1(SW)xHACII mice.

We have previously shown that B cells are not required for arthritis development
in the high affinity model system – TS1xHACII mice ((Rankin et al. 2008) and Fig. 4-1a).
It is notable that B cell deficient TS1xHACII.JH-/- and B cell sufficient TS1xHACII mice
develop disease with equal penetrance and severity. Thus, to promote arthritis,
autoreactive CD4+ T cells in this system do not require B cells to function as APCs.
These results argue that the amount of self-antigen or the context in which self-antigen
is presented (by other APCs such as conventional DCs, plasmacytoid DCs,
macrophages, etc.) was sufficient to stimulate the high affinity autoreactive CD4+ T cells
in this system to elicit a sustained autoimmune response, ultimately culminating in the
development of inflammatory arthritis.

Conversely, B cells were found to significantly contribute to the development of
arthritis in the low affinity model system – TS1(SW)xHACII mice; in the absence of B
cells (through congenital or antibody mediate depletion) disease was significantly
attenuated (Fig. 4-1b and Fig. 4-5d). Our data suggest that B cells participate as APCs
rather than as a source of arthritogenic autoantibodies (Fig. 4-2, 3, 5, 6) to drive disease
in this system. Although we found that B cells are capable of promoting autoreactive
effector CD4+T cells (both IFN-- and IL-17-producing) in TS1(SW)xHACII mice, reduced
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frequencies of IL-17+ (but not of IFN-+) V8.3+V10+CD4+ T cells correlated with the
absence of disease in TS1(SW)xHACII.JH-/- mice. Thus, these results suggest that B
cells promote disease in this system by participating as APCs for autoreactive Th17
cells. Notably, these results show that B cells in particular (and not other APCs) are
necessary to generate effector CD4+ T cells with autoreactive specificity, supporting the
findings of other studies (Chan et al. 1999, O'Neill et al. 2005, Hamel et al. 2008, Wilson
et al. 2012). So why are B cells required in the low affinity TS1(SW)xHACII model but
not in the high affinity TS1xHACII model? It is possible that B cells promote autoreactive
effector CD4+ T cell formation in TS1xHACII mice as well. If this is the case, and as
TS1xHACII.JH-/- were found to still develop severe arthritis (Fig. 4-1), it would suggest
that low numbers of cytokine-producing 6.5+CD4+ T cells would be sufficient to drive
disease. Speculating further, low numbers of autoreactive effector CD4+ T cells may be
sufficient in the high affinity but not the low affinity model system because T cells in the
former are measurably more self-reactive than in the latter (Fig. 3-7). Thus, B cells may
be necessary to generate sufficient numbers of autoreactive effector CD4+ T cells in
TS1(SW)xHACII mice in order to surpass a threshold, which when breached, results in
the loss of self-tolerance.

We also speculate on how can B cells support Th17 cells with autoreactive
specificity in TS1(SW)xHACII mice. Several reports in the literature have demonstrated
that B cells can support the formation of antigen-specific effector CD4+ T cells in
response to both foreign antigens and autoantigens, including studies in the PGIA model
of arthritis (Chan et al. 1999, O'Neill et al. 2005, Crawford et al. 2006, Hamel et al. 2008,
Wilson et al. 2012). However, less is known about if and how B cells can specifically
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promote Th17 cell differentiation (Hamel et al. 2008, van de Veerdonk et al. 2011, Wang
and Rothstein 2012). It is generally accepted that a TCR stimulus in the presence of a
Th17 polarizing cytokine milieu (TGF-, IL-6, IL-23) are required for Th17 cell
differentiation in vitro (Langrish et al. 2005, Park et al. 2005, Bettelli et al. 2006, Mangan
et al. 2006). We do not believe a difference in cytokine milieu is the causative factor for
why lower frequencies of clonotypic Th17 cells were found in TS1(SW)xHACII.JH-/- mice
compared to TS1(SW)xHACII mice. This is because the frequency of IL-17+ cells within
the total CD4+ T cell population was only marginally affected, if at all, in the absence of B
cells (Fig. 4-3 and Fig. 4-6). So it reasons that the causative factor may be how antigen
is presented by B cells. In support of this, a recent study demonstrates that naïve B-1 B
cells were more capable of promoting Th17 cells than naïve B-2 B cells; however, B-2 B
cells, upon activation, acquired the ability to promote Th17 cells, which they suggest was
due to the upregulation of certain co-stimulatory molecules (Wang and Rothstein 2012).
These findings imply that the context with which CD4+ T cells receive their antigenic
stimulation may matter. Additionally, a study with human CD4+ T cells demonstrated
that a low-strength TCR signal was more proficient at inducing Th17 cells compared to a
high-strength TCR signal (Purvis et al. 2010). In line with this, clonotypic CD4+ T cells in
TS1(SW)xHACII mice were more likely to differentiate into Th17 cells compared to
clonotypic CD4+ T cells from TS1xHACII mice (Fig. 3-9). This concept is not unique as
elaborate work examining TCR-pMHC interactions demonstrate that the strength and
context of TCR engagement can indeed influence T cell differentiation and fate (Corse et
al. 2011).
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Thus, our data demonstrate that the requirement for B cells in autoimmune
settings can be determined by the affinity of CD4+ T cells for self-antigen. Additionally,
these data also attribute B cells as unique APCs necessary for the formation of selfreactive effector CD4+ T cells.

5.4 Summary

In conclusion, our work has demonstrated that the affinity with which CD4+ T cells
recognize a single target self-antigen can have profound effects on the development of
autoimmunity. Although the factors which promote disease development in TS1xHACII
and TS1(SW)xHACII mice were distinct, both anti-TNF treatment of TS1xHACII mice
and B cell elimination in TS1(SW)xHACII mice appeared to prevent arthritis development
at least in part by disrupting Th17 cell activity, albeit by different mechanisms.
Additionally, Th17 cells also appear to promote disease in several other mouse models
of inflammatory arthritis (Lubberts et al. 2001, Nakae et al. 2003, Hirota et al. 2007, Wu
et al. 2010). Therefore, outcomes of clinical trials utilizing reagents that block IL-17
activity would be of interest (Genovese et al. 2010). It is also possible, though, that the
commonality of Th17 cell participation in inflammatory arthritis development is a
phenomenon only observed in mice.

While there has been recent success in the use of biological therapeutics to
modulate the immune system in patients with inflammatory arthritis, the factors that
determine which cellular pathways are required for disease development in individual
patients remain poorly understood. One reason that the therapeutic targeting of distinct
cellular pathways (e.g. anti-TNF versus anti-CD20 treatment) may be effective in
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different individuals could be that the cellular antigens being recognized in those
individuals are different. This possibility is difficult to assess in human patients, not least
because the antigens that are recognized by autoreactive lymphocytes in inflammatory
arthritis (such as can occur in RA and SLE) remain poorly understood (Bennett et al.
2003, Trouw and Mahler 2012). Our studies here have used a system in which the
identity of an eliciting surrogate self-peptide is known, and have shown that the overall
reactivity of the autoreactive CD4+ T cell response can determine whether or not B cells
and TNF are required for arthritis development. Furthermore, our studies have
demonstrated that stochastic events, such as TCR repertoire formation, play a larger
role in determining the course of autoimmune disease development than may have been
previously appreciated. Moreover, the observation that there is a female gender bias in
arthritis development in TS1(SW)xHACII mice, but not in TS1xHACII mice, suggests that
additional pathways (e.g. estrogen-induced immune activation) (Cutolo et al. 2002,
Behrens et al. 2010) are also necessary for arthritis development in the context of a
relatively weak autoreactive CD4+ T cell response. As antigens that are recognized in
human patients become better characterized, it will be of interest to determine whether
the level of autoreactive CD4+ T cell reactivity can predict the cellular pathways that are
required for arthritis development and determine the efficacy of distinct classes of
biological modifiers.
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